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Chapter 1 
Introduction 
2 
1.1. Folate metabolism. 
1.1.1. Biochemistry of cobalamin and folates. 
Cobalamin. Cobalamin, or vitamin B,:z, is a dietary factor which plays an indispensable 
role in the proliferation of hematopoietic cells. Since the discovery by Minot and 
Murphy in 1926 that a fatal form of anemia (pernicious anemia) could be treated by 
excessive consumption of liver (1), the structure and function of this so-called 
"extrinsic factor" (2) have been a challenge for scientists. The specific compound was 
purified from liver and isolated in crystalline form in 1948 (3,4) and called vitamin 
B,2• Its complex three-dimensional structure was elucidated by Dorothy Hodgkin in 
1956 (5) (see figure 1.1). 
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Figure 1.1: Structure of the cobalamin molecule and the (an)organic anionic ligands that can be attached 
to it at "X". 
The core of the molecule consists of a corrin ring with a central cobalt atom which 
clarifies its present name: cobalamin (6). The corrin ring, like a porphyrin, has four 
pyrrole units. Two of them are directly bonded to each other, the others are joined by 
methene bridges. The side chains on the pyrrole rings are methyl, propionamide or 
acetamine groups, as is shown in figure 1.1. A cobalt atom is bonded to the four 
pyrrole nitrogens. Below the corrin plane a fifth bond is always occupied by a 
derivative of dimethylbenzamidazole, containing ribose-3-phosphate and 
amino-isopropanol. The aminogroup of the latter is also linked with a side chain of 
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the corrin ring. Finally a sixth position, located above the corrin plane, can be either 
-CN, -CH3, -OH or deoxyadenosyl (see figure 1.1). The oxidation state of the cobalt 
atom in the cobalamin molecule can be either cob(I)-, cob(Il)-, cob(ill)alamin. 
In cyano- and hydroxycobalamin, the cobalt atom is trivalent. However, the 
biosynthesis of adenosyl- or methylcobalamin requires the reduction to cob(I)alamin 
before these organic anionic ligands can be attached to the molecule. Cobalamins can 
only be synthetized by bacteria and are not present in plants. A number of 
cobalamin-dependent bacterial enzymes has been described for both methylcobalamin 
and adenosylcobalamin. However, in man only one coenzyme function for each 
cobalamin form has been extensively documented. Methylcobalamin is required as a 
cofactor in the methylation of homocysteine to methionine by methionine synthase 
(7-9) (E.C.:2.1.1.13), which is an important step in the folate metabolism. 
Adenosylcobalamin is the coenzyme of the mitochondrial enzyme methylmalonyl CoA 
mutase which catalyzes the intramolecular isomerisation of methylmalonyl CoA to 
succinyl CoA (10,11). Methylmalonyl CoA is formed from isoleucine and valine and 
also from odd-chain fatty acids and therefore this cobalamin-dependent pathway 
forms a link between the lipid catabolism and the citric acid cycle. 
In the literature, the impaired activity of either cobalamin-dependent enzyme is 
proposed to explain the neuropsychiatric abnormalities that can be found during 
cobalamin deficiency (12). Decreased methionine synthase activity would cause 
reduced methylation of the "myelin basic protein" (13). On the other hand it has been 
suggested that impaired activity of methylmalonylCoA mutase causes deranged 
biosynthesis of myelin (14). 
Folates. Folate compounds are a group of derivatives essentially consisting of a 
substituted pteridine, p-aminobenzoate and glutamate (15) (see figure 1.2) and were 
first isolated from plant leaves (16). The parent compound pteroylglutamic acid, also 
called folic acid, is normally not found in foods or in the human body. It is 
biochemically not active but becomes so after reduction, with the attachment of 
additional hydrogens on position 5,6,7 and 8 of the pteridine ring. This reduced form, 
which is called tetrahydrofolate (THF), can be further modified by covalent binding 
of a one carbon unit at nitrogen atom 5 and/or 10. This unit can exist at several 
oxidation states (see figure 1.2) which are interconvertable. Besides reduction of the 
pteridine ring and addition of one carbon unit, folates can also be changed by the 
additional coupling of glutamic acid residues through peptide bonds with the 
glutamate already present (17,18). The so formed folylpolyglutamates mainly contain 
3-6 glutamate residues and possess properties significantly different from the parent 
folatemonoglutamate (see also 1.2). 
1.1.2. Folate metabolism in mammalian cells. 
The folates present in food are predominantly polyglutamates (15) which are 
completely converted to monoglutamates by specific conjugases during their transit 
through the intestinal mucosa (19). Moreover, all folates are converted in 5-methyl-
THF, the plasma folate form, before entering the circulation (20). Plasma 
5-methylTHF enters the cell through a membrane carrier of which the activity is 
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Figure 1.2· Structure of tetrahydrofolate molecule and the various substitutions that can be attached to 
nitrogen 5 and/or nitrogen 10. 
probably regulated by the intracellular level of folate (21-24). The exact mechanism 
through wich the folate uptake proceeds is still subject to dispute. Internalized 
5-methyllliF enters the pool of active folate coenzymes after conversion to 11IF by 
methionine synthase (enzyme 1, figure 1.3), which concomitantly methylates 
homocysteine to methionine (7-9). This reaction is dependent on the intact function 
of the methylcob(I)alarnin coenzyme. In addition, S-adenosylmethionine (SAM) is 
catalytically active in this reaction (9,25,26). 11IF is involved in several pathways 
(27-29). Serine hydroxyrnethyltransferase (enzyme 2, figure 1.3) catalyses the 
conversion of serine to glycine, while forming 5,10-methylenelliF. In mammalians, 
this pathway predominantly provides the one carbon units for the folate metabolism. 
Another metabolic route, which also leads to the synthesis of 5,10-methylenelliF is 
via 10-forrnyllliF and 5,10-methenyllliF. These consecutive steps are performed by 
5 
3 enzymatic activities present on one polypeptide (30), which is therefore called the 
"trifunctional enzyme" (enzyme 3,4,5, figure 1.3). The enzyme 5,10-methyleneTIIF 
reductase (enzyme 6, figure 1.3) catalyses the formation of 5-methylTIIF in which the 
one carbon unit exists in its most reduced state. This reaction is unidirectional (31,32) 
and under allosteric regulation by SAM (33,34). The folate coenzyme 5,10-methylene-
TIIF is also very important as it is involved in the thymidylate ( dTMP) synthesis from 
uridylate (dUMP) by dTMP synthase (enzyme 7, figure 1.3). This reaction provides 
the only pathway for de novo synthesis of dTMP necessary for DNA synthesis. The 
reaction product DHF is rapidly converted to TIIF by DHF reductase (enzyme 8, 
figure 1.3). The importance of folate-dependent dTMP synthesis has resulted in the 
chemotherapeutic use of several antimetabolites directed towards the 2 enzymes just 
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2: serine hydroxymethyltransferase 
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5: 5,1 a-methylene THF-dehydrogenase 
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Figure 1.3: Scheme of the most important folate-dependent pathways and the enzymes involved. 
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mentioned. Notably 5-fluorouracil (inhibiting dTMP synthase) and methotrexate 
(inhibiting DHF reductase) have achieved widespread application in the treatment of 
neoplastic diseases (35,36). 
Two enzymes involved in the de novo synthesis of purines also use folate 
coenzymes. Formylation of glycinamide ribotide (GAR) by 5,10-methenylTHF 
provides carbon no. 8 of the purine molecule and is catalysed by GAR transformylase 
(enzyme 9, figure 1.3). The second reaction involves formylation of aminoimidazole 
carboxamide ribotide by 10-formylTHF to add carbon no. 2, which closes the purine 
ring to form inosinic acid (AICAR transformylase, enzyme 10, figure 1.3). 
The levels of the different folate cofactors in tissues and the activity of the related 
enzymes is very dependent on the function and proliferative state of the studied cells. 
Moreover a distinct compartimentalisation of the folate coenzyme pools has been 
observed in liver cells (37). In resting cells 5-methylTHF is the predominant folate 
form present (38-42) while in rapidly dividing tissues equal levels of 5-methylTHF and 
10-formylTHF exist (40,43-45). Moreover, nutrional deficiencies of either cobalamin 
(46-49), or methionine (47,50-60) exert direct effect on the distribution of intracellular 
folates among the various coenzyme pools. 
An increasing body of evidence indicates that retention and concentration of folates 
in mammalian cells requires the conversion of folate to polyglutamate derivatives by 
polyglutamate synthetase (17,18). The observed end-product inhibition of long-chain 
folylpolyglutamates on this particular enzyme probably effects steady-state 
intracellular folate concentrations (61,62). Not surprisingly, folylpolyglutamate 
synthetase is the most active in rapidly proliferating cells, presumably because of low 
intracellular folate levels after cell division. 
The level of polyglutamation of the various folate coenzyme forms plays an 
essential role in the regulation of the folate metabolism as the affinity of folate 
coenzymes for several enzymes can depend on the level of polyglutamation (63,64). 
Notably monoglutamate forms have proven to possess the lowest affinity towards 
folate-dependent enzymes (18). Moreover, 5-methylTHF has shown to be a poor 
substrate for polyglutamation (65-71) and therefore requires the cobalamin-dependent 
conversion to THF before glutamate residues can be added, by which its intracellular 
retention increases (65,72). This particular property of 5-methylTHF further 
emphasizes the key role of methionine synthase in cellular folate metabolism. 
1.1.3. Cobalamin, folate and methionine metabolism. 
The cobalamin-dependent enzyme methionine synthase plays an important role in the 
methionine metabolism as it provides the most common pathway for the regeneration 
of this amino acid from homocysteine (7-9). Its significance is evidenced by the 
elevated levels of plasma homocysteine in patients with inborn errors of 5-methylTHF 
(73,74) or methylco.balamin metabolism (75-77). Moreover, perturbation of other 
pathways of the folate metabolism (78) or folate and cobalamin deficiency (79) also 
result in raised levels of circulating homocysteine. 
The synthesis of methionine through methionine synthase is regulated in several 
ways. First of all methionine itself exerts some negative feedback on the activity of 
the enzyme through end product inhibition (9,50,80). Secondly, methionine is 
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Figure 1.4: Scheme of the most important pathways of the methionine metabolism. 
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converted to S-adenosylmethionine (SAM, see figure 1.4). This high energy compound 
is considered to have a regulating effect on folate-dependent methionine synthase 
through strong allosteric inhibition of 5,10-methyleneTIIF reductase (33,34), by which 
the amount of 5-methylTIIF available for methionine synthesis is reduced. Moreover, 
8 
it has been shown that SAM is catalytically active in the actual methionine synthase 
reaction (9,25,26). Thus, low methionine and low SAM concentrations, as in 
methionine deficiency, lead to accumulation of 5-methyllHF at the expense of other 
reduced folates. On the other hand, high concentrations of SAM result in reduced 
5-methyllHF levels. However, most research on this subject has been conducted in 
liver tissues (47,49-58), and its significance for other cell types has yet to be 
elucidated as some controversial results have been published (81,82). For instance, 
addition of low doses methionine to cobalamin deficient bone marrow cells are able 
to correct disturbed folatedependent dTMP synthesis while high doses aggrevate the 
disturbances of the folate metabolism (83). 
The alternative route for methionine synthesis leads via betaine homocysteine 
methyltransferase but only exists in liver and probably kidney. The enzyme appears to 
adopt its activity to the supply of methionine, betaine and choline (a precursor of 
betaine), but is considered to be of minor importance (84-86). 
Besides its regulatory function in the folate metabolism SAM is important as the 
major donor of methylgroups in a wide variety of transmethylation reactions and also 
the precursor of decarboxylated SAM, necessary for polyamine synthesis (see figure 
1.4). The co-product of these transmethylations, S-adenosylhomocysteine, is hydrolysed 
to yield homocysteine which can be remethylated to methionine or condensed with 
serine to form cystathionine (84,86,87). 
1.2. The importance of cobalamin-dependent folate metabolism in hematopoiesis. 
1.2.1. Megaloblastic anemia 
The direct importance of cobalamin for the maintenance of hematopoiesis is evident 
from the severe anemia which may develop in case of cobalamin deficiency. Already 
in 1849 Addison described a fatal form of anemia characterized by the presence of 
abnormal large cells in the bone marrow which were named megaloblasts by Ehrlich 
(88). In 1926 it was found that this particular syndrome (pernicious anemia) could be 
effectively treated with an extract from liver (1), which finally resulted in the 
discovery of vitamin B12 or cobalamin. The underlaying cause of anemia turned out to 
beimpaired absorption of cobalamin through the absence of Castle's intrinsic factor 
(2), which on its tum is caused by a proces of autoimmune atrophic gastritis (89,90). 
In 1931, Lucy Wills isolated from yeast a second factor, which was capable to 
correct megaloblastic anemia of pregnancy and tropical sprue (91). Later on, this 
compound was also isolated from plant leaves and therefore called folic acid (92). 
These clinical observations resulted in the recognition of folate deficiency as a 
separate cause of megaloblastic anemia (93). The clinical similarity of either 
cobalamin or folate deficiency led to intensive research on the possible functional 
relationship between these two vitamins and more specifically their actual role in the 
proliferation of hematopoietic progenitor cells. Up till now, the only known metabolic 
pathway common to both folate and cobalamin is the reaction catalysed by 
methionine synthase (see figure 1.5), in which homocysteine is methylated to 
methionine (7-9). Based on this knowledge and some clinical observations in patients 
with cobalamin deficiency, Noronha & Silverman (46) and Herbert & Zalusky (94) 
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advanced the "methylfolate trap" hypothesis to explain the effect of cobalamin 
deficiency on hematopoietic proliferation. 
5-melhyi-THF THF 
Cob (I) alamin H3C-cob (I) alamin 
COOH >--< COOH 
H-t-CH,-CH,-5-CH, H-t-CH,-CH,-SH 
~~ ~~ 
methionine homocysteine 
Figure 1.5: Outline of the enzymatic transfer of the methyl group of 5-methylTHF to homocysteine 
through cob(I)alamin. 
1.2.2. The methylfolate trap hypothesis 
Based on the role of cobalamin in the methionine synthase reaction and the elevated 
serum folate levels in patients with cobalamin deficiency, the "methylfolate trap" 
states that under conditions of cobalamin deficiency methionine synthase activity is 
diminished (95) and folate is "trapped" as 5-methylTHF. Since reoxidation via the 
5,10-methyleneTHF reductase pathway is impossible under physiological conditions 
(31,32), a functional deficiency of all other reduced folate forms ensues, causing 
impairment of folate-dependent reactions. The subsequent reduction of synthesis of 
dTMP and purines decreases DNA replication and results in reduced proliferation of 
the hematopoietic progenitor cells. 
The main implications of this "methylfolate trap" are a relative accumulation of 
5-methylTHF in cobalamin-deficient tissues and the correction of cellular 
proliferation by all reduced folates with the exception of 5-methylTHF. Both 
consequences have been thoroughly studied and have been demonstrated to be 
correct (resp. 46-49,96 and 97-105), although the actual demonstration of increased 
tissue levels of 5-methylTHF has been difficult because of the low intracellular folate 
content and the instability of the various folate coenzyme forms.Twenty-eight years 
after postulation of the "methylfolate trap" as an explanation for the cobalamin 
deficiency-induced megaloblastic anemia, the quintessence of this hypothesis still 
stands, although some modifications appeared necessary. 
First of al~ ameliorating effects of methionine on some features of disturbed folate 
metabolism (e.g.: increase of deranged folate-dependent histidine degradation 
(51,54,57) and intracellular folate repletion (47,50,56,58) had to be accounted for by 
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the inhibiting effect of SAM on 5,10-methyleneTHF reductase (33,34) and the 
catalytic action of SAM in the methionine synthase reaction (9,50,80) (see figure 1.4). 
The consequences of this regulation mechanism are both reduced synthesis and 
accumulation of 5-methylTHF during methionine supplementation of 
cobalamin-deficient subjects. 
Secondly the "methylfolate trap" had to be expanded to explain the lowered tissue 
folate levels in cobalamin-deficient animals. Both the recognition that polyglutamation 
of folates is essential for their intracellular retention ( 65), and the observation that 
5-methylTHF is a poor substrate for folylpolyglutamatesynthase (65-71) have provided 
the key to this problem. Since internalized 5-methylTHF cannot be converted to other 
reduced folate forms in case of cobalamin deficiency, insufficient polyglutamation 
occurs, causing decreased uptake and retention of folates in tissues. 
Based on the "methylfolate trap" Killman et al. (105) developed a functional test 
which could discriminate between cobalamin and folate deficiency as the primary 
cause of megaloblastic anemia. In marrow cells from megaloblastic patients 
folate-dependent dUMP methylation to dTMP is very low. Incubation of marrow cells 
with deoxyuridine ( dU) prior to rH]thymidine incubation hardly reduces the 
incorporation of the latter in DNA However, preincubation of these cells with 
cobalamin or folic acid will restore the folate-dependent dTMP synthesis and 
decrease the cellular rH] thymidine incorporation in DNA The specific correction 
pattern by cobalamin and/ or folic acid is indicative for either deficiency 
(102-104,106). 
Although a vast amount of experimental evidence exists, which is in agreement with 
the "methylfolate trap" hypothesis, several other theories have been presented for the 
interrelationship between folate, cobalamin and methionine metabolism. Most 
importantly, Chanarin et al. proposed the "formate starvation" hypothesis as 
alternative explanation for the phenomena which can be observed during cobalamin 
deficiency. 
1.2.3. The formate starvation hypothesis 
Essentially, this explanatory theory by Chanarin and coworkers emphasizes the 
importance of the reduced methionine synthesis during cobalamin deficiency 
(107-110). They observed that, compared with THF, 5-formylTHF was superior in 
correcting disturbed folate-dependent dTMP synthesis in bone marrow cells and 
therefore concluded that the THF production by methionine synthase is of little 
importance for cellular folate metabolism (111-114). Instead they proposed that 
decrease of methionine supply is the actual cause of disturbed folate metabolism.The 
metabolic link between those two is based on the conversion of methionine to "active 
formate" via a 5~steps pathway (see figure 1.6). In addition they found that the 
formate precursors methionine and SAM could restore the impaired 
folylpolyglutamate synthesis (115-117). Low methionine concentrations would cause 
reduced formate levels and therefore impair synthesis of formylTHF which is 
considered to be the optimal substrate for folylpolyglutamate synthesis (114). Over 
the years Chanarin et al. have published a vast amount of interesting studies, the 
results of which were always interpreted in favor of the formate starvation theory. 
folate 
metabolism 
homocysteine 
5-methyl THF THF 
Figure 1.6: Pathway of formate synthesis from methionine as postulated by Chanarin et al .. 
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Still, it seems rather unlikely that "formate starvation" is the primary cause of 
impaired hematopoiesis during cobalamin deficiency. The proposed pathway for 
formate production seems rather complicated and direct administration of sodium 
formate to rats with a functional cobalamin deficiency does not result in restoration 
of the intracellular folate homeostasis (117). Moreover, the observation by Chanarin 
et al that 5-formylTHF is the preferable substrate for polyglutamate synthesis has not 
been confirmed by others (67,71). The demonstrated superiority of 5-formylTHF over 
THF in correcting disturbed deoxyuridine suppression tests from cobalamin-deficient 
bone marrow cells may well be attributed to its greater stability and its more effective 
uptake by cells (28). 
1.2.4. Cobalamin-dependent folate metabolism in malignant hematopoiesis 
The folate metabolism has been an important target for cancer chemotherapy ever 
since Faber demonstrated the effectiveness of folic acid analogues in leukemia 
treatment (118). Notably methotrexate is succesfully used in the management of 
various malignancies and currently incorporated in most treatment protocols for acute 
12 
lymphoid leukemia (36). Recently, antileukemic effect of 5-fluorouracil (119) and 
CB3717 (120), both inhibitors of the folate-dependent dTMP synthase has also been 
demonstrated in the Brown Norway model for myeloid leukemia (BNML). 
Clinical resistance to antifolates especially methotrexate has been observed in 
several malignancies (36). It can be caused by increased DHFR levels, changes in the 
kinetic properties of DHFR or reduced uptake and/ or polyglutamation of the 
antifolate. The occurence of drug resistance stimulated the development of new folate 
derivatives directed against one of the various folate-dependent enzymes directly or 
indirectly involved in dTMP or purine synthesis (121). For instance CB3717 
(N10-propargyl-5,8-dideazafolic acid) acts primarily on dTMP synthase and DDATHF 
(5,10-dideazatetrahydrofolic acid is an inhibitor of the enzyme glycinamide ribotide 
transformylase. Until now, however, only little progress has been made on the 
inhibition of the cobalamin-dependent methionine synthase reaction as a possible 
chemotherapeutic target. It is very probable that this particular enzyme plays a vital 
role in the proliferation of leukemic and other malignant cells as it does in normal 
hematopoietic and other tissue proliferation. In two patients acceleration of leukemic 
growth has been observed after cobalamin supplementation, administered for the 
treatment of a megaloblastic anemia (122,123). Levels of both cobalamin and folate 
are elevated in leukemic cells as compared with normal bone marrow cells (124-127) 
and the activity of methionine synthase is also increased, especially in lymphoid 
leukemia (128-131). Kroes et al. demonstrated the antileukemic effect of impaired 
methionine synthase activity in the BNML using nitrous oxide to inactivate the 
cobalamin coenzyme (132). Moreover they demonstrated enhanced chemotherapeutic 
activity of several drugs that interfere with the folate metabolism if combined with 
cobalamin inactivation (133-136, see also 1.3.4.: Effects of nitrous oxide on malignant 
hematopoiesis). Regarding the importance of folate metabolism for malignant 
proliferation, the specific exploration of cobalamin-dependent methionine synthase as 
a potential target in cancer chemotherapy seems justified (137). 
1.3. The effect of nitrous oxide on cobalamin. 
1.3.1. History. 
Nitrous oxide is a colorless, odorless gas, which already has been applied in 
anesthesia for more than a century. Although it is not a very potent anesthetic, it has 
gained general application as an adjuvant to other anesthetics. Presently, a gas 
mixture of 70 % nitrous oxide/30 % oxygen is commonly used to ventilate 
anesthetized patients. During almost a century the use of nitrous oxide had been 
considered to haveno significant side-effects. However, clinical observations in tetanus 
patients in the fifties revealed that prolonged inhalation of nitrous oxide could result 
in megaloblastic and aplastic bone marrow depression (138-140). Later studies in 
rodents demonstrated a striking leukopenia during nitrous oxide exposure which, 
however, was not accompanied by megaloblastic changes in the bone marrow 
(141-145). 
Until 1978 the observed hematological toxicity of nitrous oxide remained 
unexplained but this changed when Amess et al. (146) and Deacon et al. (147) 
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correlated the occurrence of megaloblastic anemia in nitrous oxide-treated patients 
with the chemical reaction between cobalt (I) complexes, like reduced cobalamin, and 
nitrous oxide. This specific reaction between transition-metal complexes and nitrous 
oxide, already described in the chemistry literature in 1968 (148,149), results in the 
oxidation of cob(I)alamin to cob(ll)alamin. Since this explanation of nitrous 
oxide-induced megaloblastic anemia, further research, has been aimed at the 
elucidation of the mechanism of cobalamin inactivation by nitrous oxide and its 
consequences for mammalian folate metabolism. Moreover, the phenomenon 
provided experimenters with a easy tool to further investigate the metabolic effects of 
cobalamin deficiency, which otherwise is rather difficult to induce in laboratory 
animals. 
1.3.2. Effect of cobalamin inactivation on folate metabolism. 
Effect on methionine synthase. The inactivation of the cobalamin coenzyme of 
methionine synthase by nitrous oxide has been studied thoroughly both in vitro and in 
vivo.Recently, the gene encoding for the enzyme has been cloned (150) and the 
resulting availability of large amounts of pure and active enzyme will surely facilitate 
research into the specific mechanism of the methionine synthase-catalysed reaction 
and its inactivation by nitrous oxide. The proposed mechanism of oxidation of the 
cobalamin coenzyme is as follows (150,151): 
Cob(I)alamin + N20 + H+ -----> Cob(TI)alamin + N2 + OH 
The generation of a hydroxyl radical at the active site of the enzyme is responsible for 
the irreversible loss of catalytic activity and it also causes partial destruction of the 
cobalamin prosthetic group. The actual in vivo inactivation of methionine synthase by 
nitrous oxide has now been demonstrated in a variety of species and tissues 
(147,151-162). Studies by Royston et al. (163) have shown that rat methionine 
synthase is inactivated at a higher rate (t!Wl: 5 min.) than the human enzyme (t!Wl: 45 
min.). The latter implicates that effects of nitrous oxide exposure on human folate 
metabolism occur only after several hours of exposure. Indeed some studies revealed 
that it takes at least 5-6 hours before the deoxyuridine suppression tests in bone 
marrow cells becomes abnormal (164). 
During exposure to nitrous oxide no recovery of the enzyme activity (less than 10 
% of control values) occurs (155,160). Withdrawal of the gas results in slow recovery 
of methionine synthase activity within several days. 
Effects on intracellular folate metabolism. The primary effect of cobalamin inactivation 
is the disturbed methylation of homocysteine by 5-methylTHF. Secondary to this 
event a cascade of biochemical changes in the folate-dependent metabolism occurs 
which altogether seems to concur with the methylfolate trap hypothesis. Tissue folate 
levels decrease (165-167) because of the impaired metabolisation of internalized 
5-methylTHF arid because the relative increase of this "trapped" folate form (166-168) 
reduces folylpolyglutamation (68,116,117,166,169). Subsequently, rates of purine 
(162,170-172) and dTMP synthesis, both dependent on folate coenzymes, decrease. 
14 
The latter has been thoroughly studied, using the deoxyuridine suppression test as 
described before (111,164,173-179). 
The defective methionine synthesis also causes a drop in tissue levels of methionine 
as well as SAM (179-181), and a decrease of plasma methionine (159,178,182,183). 
Noteworthy a rise of plasma homocysteine has only been shown in rats (184). After 
several days of nitrous oxide exposure some replenishment of methionine levels in rat 
liver occurs, probably by induction of the alternative homocysteine-betaine 
methyltransferase pathway (179). Finally, nitrous oxide exposure disturbs several 
catabolic pathways, notably the oxidation of formate, produced during methanol 
poisoning, (168,180,185, 186), and the degradation of histidine (180,187), which 
require THF and become impaired by cobalamin inactivation. 
Cobalamin-folate homeostasis during nitrous oxide exposwe. Only a few studies have 
been performed on the actual effect of nitrous oxide on the tissue cobalamin levels. A 
slow decrease was found in rats and fruit bats (154,188,189). Moreover, the formation 
and excretion of cobalamin analogues has been reported (189), which concurs with 
the suggested damage to the cobalamin molecule by nitrous oxide (150,151). 
Tissue folate levels decrease during nitrous oxide exposure and this is accompanied 
by an increased loss of folates with the urine (190). The recovery of tissue folate 
levels requires the dietary intake of new folate (191). 
1.3.3.Effect of nitrous oxide on normal hematopoiesis: implications of its clinical use. 
The disturbance of folate metabolism by nitrous oxide results in hampering of 
impaired cellular proliferation because of reduced nucleotide synthesis. Just like in 
cobalamin deficiency, the dependence of hematopoiesis on the intact function of the 
cobalamin coenzyme of methionine synthase becomes evident by exposure to nitrous 
oxide.Before the interaction between nitrous oxide and cobalamin was recognized, 
Lassen et al. had described several cases of severe bone marrow depression after 
prolonged exposure to nitrous oxide (138). Since the rediscovery of this toxic effect by 
Amess et al. ( 146), several studies have been conducted in order to determine the 
risks of bone marrow depression during nitrous oxide anesthesia. Normaly it takes 5-6 
hours of exposure before dTMP synthesis becomes depressed (164), and 12-24 hours 
before macrocytic/megaloblastic changes can be seen in the bone marrow (146,177, 
178). 
Presently, in most cases anesthesia is too short to cause significant hematological 
toxicity. Moreover, a temporary reduction of hematopoiesis may well be dampened by 
the vast pool of mature blood elements in the blood and bone marrow. However, in 
case of multiple nitrous oxide exposures (192) (e.g. trauma patients), seriously ill 
patients (193) or subjects with a marginal or manifest cobalamin and/or folate 
deficiency (194), bone marrow depression may already develop within 2 hours. A 
special situation occurs when nitrous oxide anesthesia is given prior to the 
administration of a folate antagonist Recently, several reports have drawn attention 
to the interaction between nitrous oxide and methotrexate causing unexpected 
gastrointestinal toxicity and myelosuppression in cancer patients (195-197). 
Despite the apparent hematological side effects of nitrous oxide it has maintained a 
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remarkable record of safety for over a century. Considering the possible toxicity of 
other anesthetics it may be concluded that nitrous oxide is still an extremely useful 
analgesic/anesthetic agent but one must remain aware of hematological side effects in 
some patients. Noteworthy, supplementation with folinic acid (5-formylTHF) has 
proven to provide adequate protection against the myelosuppressive effects of this 
anesthetic gas (198,199). 
1.3.4. Effects of nitrous oxide on malignant hematopoiesis: possible applications. 
Already 3 years after their publication of the nitrous oxide-induced bone marrow 
depression, Lassen and coworkers reported on the succesful application of nitrous 
oxide in the treatment of 2 patients with chronic myelogenous leukemia (200). They 
observed a remarkable drop in the leukocyte counts but this effect was always quickly 
reversed upon withdrawal of the nitrous oxide. A few years later, Eastwood et al. 
used nitrous oxide in the treatment of 2 cases of acute myeloid leukemia with 
comparable results (201) and recently Ikeda et al. described effective reduction of 
peripheral leukocytes and size of the spleen in a case of chronic myelogenous 
leukemia (202). 
Besides these few clinical reports no data are available on the effect of nitrous 
oxide on human leukemia. In vitro however, a specific sensitivity of hematological cell 
lines for nitrous oxide has been observed in the deoxyuridine suppression test and in 
reduced cell growth (203). Moreover a differentiation inducing effect of nitrous oxide 
on the promyelocytic HL-60 cell line has been described, which is probably related to 
the reduced methionine synthesis during cobalamin inactivation (204). Studies in mice 
have also revealed antitumor activity of nitrous oxide in fibrosarcoma (205), Ehrlichs 
acites tumor (206) and lymphoma (207). 
Recently, an extensive study by Kroes et al. (132) demonstrated that nitrous oxide 
has antiproliferative properties in a rat model for myeloid leukemia (BNML) causing 
reduction of the leukemia-induced leukocytosis and hepatosplenomegaly. Moreover it 
was shown that the antiproliferative effect of nitrous oxide can be enhanced by 
combination with several drugs interfering with other folate-dependent pathways. 
Especially the antileukemic effects of cycloleucine (inhibitor of methionine 
adenosyltransferase ), methotrexate (inhibitor of dihydrofolate reductase) and 
5-fluorouracil (inhibitor of thymidylate synthase) could be strongly potentiated by 
preexposing rats to nitrous oxide (133, 134-135). Administration of 25 mg/kg 
5-fluorouracil after three days nitrous oxide exposure, repeated every five days, 
resulted in almost 200 % extended survival time of the leukemic rats. Cobalamin 
inactivation by nitrous oxide combined with methylglyoxalbis(guanylhydrazone ), an 
inhibitor of SAM decarboxylase, also reduced polyamine synthesis, which is 
considered a potential target in cancer chemotherapy. However, antiproliferative 
activity of the induced polyamine depletion in the BNML is rather limited (136). 
1.4. Introduction to the experimental work. 
This thesis deals with several aspects of the effects of cobalamin inactivation by 
nitrous oxide on cellular folate metabolism and the consequences on normal and 
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malignant hematopoiesis. Kroes et al. demonstrated the antileukemic effects of 
nitrous oxide either or not in combination with other drugs interfering with the folate 
metabolism (132-136). Especially the potentiation of methotrexate activity in the 
employed rat model for myeloid leukemia (BNML) after preexposure to nitrous oxide 
was striking (134). 
Based on those findings part of the work presented in this thesis focuses on the in 
vivo interaction between nitrous oxide and methotrexate. In order to establish the 
cytotoxicity of the nitrous oxide-methotrexate combination for normal cells, we 
conducted an extensive toxicological study in healthy rats in which we concentrated on 
the effects on the rapidly dividing cells of bone marrow and gut mucosa (Chapter 3). 
Moreover, effects of nitrous oxide and/ or methotrexate on folate metabolism and 
folate-depedent dTMP synthesis of fresh human leukemic cells were studied in order 
to clarify the actual working mechanism (Chapter 4,5). 
Kroes et al. came to the conclusion that cobalamin inactivation by nitrous oxide 
appeared applicable in the treatment of human leukemia. However, several questions 
still have to be answered before nitrous oxide can be used for this particular purpose. 
For instance, no information on a differential sensitivity of normal hematopoietic and 
leukemic cells for cobalamin inactivation is available. We therefore investigated the 
effects of nitrous oxide on both normal and malignant hematopoiesis in the BNML 
model (Chapter 2) employing in vitro bone marrow culture techniques. In this 
particular type of bioassay, bone marrow cells are cultured ex vivo in the presence of 
growth factors supporting the proliferation of the hematopoietic progenitor cells. 
These cells are very important for the maintenance of hematopoiesis and their in vitro 
quantification therefore enables assesment of normal bone marrow functioning. 
Similar in vitro bone marrow culture techniques were used to determine the effects of 
cobalamin inactivation on human bone marrow function in hematologically normal 
patients, receiving nitrous oxide anesthesia (Chapter 6). The sensitivity of the various 
forms of human leukemia for cobalamin inactivation was studied in vitro by means of 
the deoxyuridine suppression test and of measurement of the intracellular folate 
coenzyme levels (Chapter 4,5). 
Finally, on the basis of a panel of biochemical parameters in blood and urine of 
hematologically normal patients receiving nitrous oxide anesthesia the velocity of 
nitrous oxide-induced cobalamin inactivation and the recovery period is monitored in 
vivo (Chapter 7). 
In chapter 8, the presented work will be discussed in view of the present knowlegde 
on the role of the cobalamin-dependent folate metabolism in both normal and 
malignant hematopoiesis. 
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Chapter 2 
Nitrous oxide selectively reduces the pro-
liferation of the malignant cells in experi-
mental rat leukemia 
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2.1. Summary. 
A consideral reduction of hepatosplenomegaly and leucocytosis in leukemic rats of 
the Brown Norway Myeloid Leukemia (BNML) can be achieved by exposure to 50% 
nitrous oxide /50% oxygen. In this study the differential antiproliferative effect of 
nitrous oxide, inactivating vitamin B1:z. on normal and leukemic hemopoiesis was 
investigated in this rat model. Rats injected with leukemic cells and exposed to 
nitrous oxide for ten days showed 30% reduction of hepatosplenomegaly and 50% 
reduction of leukocytosis. Similarly treated healthy rats showed no signs of impaired 
hemopoiesis as measured by peripheral blood parameters. Clonogenic assays of 
erythroid and myeloid progenitors from both healthy and leukemic rats revealed that 
exposure to nitrous oxide did not suppress normal bone marrow functioning. On the 
contrary, the reduction of leukemic proliferation by nitrous oxide retarded the 
leukemic infiltration of the bone marrow compartment. 
2.2. Introduction. 
Exposure to the anesthetic gas nitrous oxide inactivates the cobalamin coenzyme of 
methionine synthetase (1). This enzyme plays an essential role in the cellular 
retention and metabolism of folate coenzymes. Nitrous oxide induced inactivation of 
cobalamin (Vitamin B12) therefore leads to secondary impairment of the 
folate-dependent synthesis of thymidylate ( dTMP), which subsequently affects DNA 
synthesis of proliferating cells (2). The continuous production of mature peripheral 
blood cells requires the rapid selfrenewal, proliferation and maturation of 
hemopoietic progenitor cells in the bone marrow. These cells have shown to be 
particularly dependent on the functional cobalamin coenzyme. For instance in 
humans, exposure to nitrous oxide for several days results in overt megaloblastic 
anemia (1,3). In rats a reversible leukopenia without other clear signs of bone marrow 
depression can be induced by prolonged exposure to the anesthetic ( 4,5). 
The importance of reduced folate metabolism for proliferating cells makes it a 
potential target for chemotherapy of malignancies as is illustrated by the frequent use 
of the antifolate methotrexate. Interference with folate metabolism by inactivation of 
methionine synthetase is only possible through exposure to. nitrous oxide. In early 
studies the use of nitrous oxide in the treatment of chronic and acute leukemia has 
shown remarkable regression of leukemia (6,7). However further trials concerning this 
antineoplastic effect of nitrous oxide have not appeared. 
In our laboratory the antiproliferative effect of cobalamin inactivation was 
investigated in a rat leukemia model, the Brown Norway Myeloid Leukemia (BNML). 
This transplantable acute leukemia has been described in detail before (8) and is 
considered to be a reliable model for chemotherapeutic studies (9). The antileukemic 
effect of nitrous oxide alone or in combination with several other agents has been 
documented before (10-14). However, the applicability of an anticancer drug is 
determined by its selectivity towards the neoplastic cells. Nowadays hemopoietic 
progenitors can be cultured in vitro. The addition of specific growth factors to these 
bone marrow cultures results in the proliferation of either myeloid or erytroid 
progenitor cells. This technique therefore provides a way to asses the normal 
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hemopoietic proliferation capacity of the bone marrow. The purpose of the present 
study was to investigate the differential effect of nitrous oxide on normal and 
malignant hemopoiesis in the BNML using the in vitro techniques decribed above. 
2.3. Materials and methods. 
Animals. Male rats of the Brown Norway inbred strain were used (body weight ± 200 
g). Food and water were supplied ad libitum during the experiments. 
Brown Norway Myeloid Leukemia. Properties of the BNML have been decribed 
before. Briefly, rats were injected i.v. with 107 leukemic cells, which after progressive 
infiltration of bone marrow, liver and spleen leads to death in 20-24 days. In the 
present study rats were evaluated 18 days after transfer of leukemia. 
Exposure to nitrous oxide. Exposure to nitrous oxide was carried out in a 40 L flow 
chamber into which a mixture of 50 % nitrous oxide and 50 % oxygen was blown at a 
rate of 500 ml per min. Rats not exposed to nitrous oxide, were kept in air but 
otherwise treated identically. 
Evaluation of leukemic growth. Two groups of 5 rats were injected with leukemic cells 
on day 0. At day 7 of leukemia one group was transferred to the flow chamber and 
exposed to nitrous oxide for 10 days. At day 18 of leukemia all rats were killed by 
exsanguination. Uver and spleen were carefully removed and weighed. Leukocytes 
and thrombocytes were counted electronically and hemoglobin concentration was 
measured by the hemoglobin cyanide spectrophotometrical assay. 
Bone marrow morphology. Femurs of 2 groups of 5 healthy rats (one group exposed to 
nitrous oxide for 10 days) were removed and cut into 2 pieces. Bone marrow was 
aspirated from the open shaft with a fine needle and used for smears. After staining 
with May-Grunwald Giemsa, one smear of each rat was used for a differential count 
of 500 cells. 
Bone marrow cultures. To quantify the hemopoietic progenitors in bone marrow of 
healthy and leukemic rats, either exposed to air or to nitrous oxide, in vitro culture 
techiques have been applied as described by Kimura et al (14). Briefly, bone marrow 
cells were flushed out of the femur with sterile Alpha DMEM medium and dispersed 
into a single cell suspension by aspiration through a 22-gauge needle. After being 
washed once, 5.Hf cells were plated in triplicate in 35 mm culture dishes in 1 ml 
Alpha medium containing 0,9 % methylcellulose, 10 % fetal calf serum, 3.10-s M 
lecthine, 1% (w/v) bovine serum albumine, transferinne 3.10-6 M and 2.10-s M 
mercaptoethanol. Growth of myeloid progenitors was supported by the addition of 10 
% rat spleen-conditioned medium as a source of growth factors (for preparation see 
also ref. 14). Erythroid precursors were stimulated by the addition of 0,5 U sheep 
erythropoietin (Step Ill, Connaught, Willowdale, Canada) per ml. Dishes were 
incubated at 37 oc for 6 days. Clusters (10-50 cells) and colonies (more than 50 cells) 
were counted with the help of an inverted microscope. 
2.4. Results. 
Table 2.1 summarizes the results of 2 experiments with either normal, healthy or 
leukemic animals exposed to air or to 50 % nitrous oxide and 50 % oxygen for 10 
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Table 1. 
Effect of nitrous oxide on hematological parameters of normal and 
leukemic brown Norway rats (mean ± sem, n = 5) 
normal rats leukemic rats 
parameters air 10d.N20 air 10d.N20 
Leukocytes (109/L) 6,5 ± 0,5 5,7 ± 0,6 18,1 ± 4,0 9,3 ± 2,1** 
Thrombocytes (1011 /L) 790 ± 34 810 ± 30 89 ± 13 85 ±4 
Hemoglobine (mM) 9,3 ± 0,5 8,2 ± 0,5 8,8 ± 0,4 9,0 ± 0,2 
days. Exposure to nitrous oxide at this concentration did not influence the behaviour 
or activity of the rats nor their nutritional condition. In healthy rats nitrous oxide had 
no statistical significant effect on the peripheral blood parameters during the 
observation period. Also differential counts of bone marrow smears did not show any 
substantial difference between the 2 treatment groups (see figure 2.1), except for a 
significant reduction of mature granulocytes (in figure 2.1 indicated as 
"polysegmented") after nitrous oxide exposure. 
In contrast, in leukemic rats 10 days exposure to nitrous oxide reduced the 
leucocyte count to about 50 %. It was accompanied by a reduction of liver weight 
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Figure 2.1: Effect of nitrous oxide on morphologic profile of normal rat bone marrow. (mean ±s.e.m. of 4 
rats) 
33 
Figure 2.2:/n vitro colony formation of erythroid (left) and granulocyte/macrophage (right) progenitors 
from rat bone marrow during development of leukemia (-: colonies, --: clusters, mean ±s.e.m. of 4 
rats) 
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Figure 2.3: Effect of nitrous oxide on erythroid (left) and granulocyte/ macrophage (right) progenitors in 
normal and leukemic bone marrow. (mean ±s.e.m. of 4 rats) 
(from 18.7±1,3 g to 16.6±1.9 g) and spleen weight (from 4.2±0.4 g to 2.8±0.1 g) as 
has been described before (10). Platelet counts in these rats, which had 
fallen during .the development of leukemia, did not show any adverse effect of the 
treatment with nitrous oxide. 
However, evaluation of treatment effects on normal hemopoiesis by solely studying 
peripheral blood parameters of the BN rat can be deceptive as lymfocytes make up 
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about 95 % of the circulating leukocytes. Moreover, effects on erythropoiesis are 
masked because of the long life span of erythrocytes. Therefore clonogenic assays 
were performed to assess the effect of nitrous oxide on the number of both erythroid 
and granulocyte/macrophage progenitors in rat bone marrow. First, groups of 4 
leukemic rats were sacrificed on day 0, 7, 11,15 and 18 of leukemia and assayed for 
both types of progenitors. Figure 2.2 shows that from day 11 on, a time dependent 
decrease of progenitor cells was observed, resulting in almost complete disappearance 
of normal hemopoiesis om day 18. 
In the next experiment a group of healthy rats and a group of leukemic rats (day 7) 
were exposed to nitrous oxide. Concomitantly, 2 similar groups were kept in air. After 
10 days all rats were sacrificed and bone marow was assayed for hemopoietic 
progenitors. Figures 2.3A and 2.3B show that there was no effect of nitrous oxide on 
the cluster and colony forming cells in healthy rats. Leukemic rats in air showed only 
residual cluster forming cells as in the experiment above. However in bone marrow of 
leukemic rats exposed to nitrous oxide a substantial number of both erythroid and 
granulocyte/macrophage cluster-forming cells was present. Moreover colony forming 
cells of the latter were still detectable after exposure to the anesthetic. 
2.5. Discussion. 
Nitrous oxide has proven to reduce the growth of the BNML in a dose dependent 
way (10). Moreover its combination with other drugs interfering with the folate 
metabolism (e.g. methotrexate and 5-fluorouracil) has shown to be very effective in 
the treatment of the applicated rat leukemia model (11-14). 
However, little attention has been paid to the treatment effects on normal 
hemopoiesis. As bone marrow depression is the most important dose limiting toxicity 
in leukemia treatment, we investigated this phenomenon in the BNML during 
treatment with nitrous oxide. 
Several studies on the effects of nitrous oxide on rat hematopoiesis revealed a dose 
dependent development of leukopenia and slight morphological changes in bone 
marrow ( 4,5). However, quantification of hemopoietic progenitors by clonogenic 
assays after nitrous oxide exposure has never been performed before. The method for 
the culture of clonogenic cells in normal rat bone marrow agreed with that of Kimura 
et al (14) except that fetal calf serum was added to the culture of erythroid precursors 
instead of rat plasma. Prins et al. (15) have shown that leukemic cells of the BNML 
particularly lodge near the endosteal sites in femoral bone marrow. As this region is 
also preferred by normal hematopoietic progenitors, a gradual replacement of 
hematopoiesis during development of leukemia occurs. This explains the observed 
decrease in platelet counts in leukemic rats. Suppression of erythropoiesis leads only 
very slow~y to a . reduction of the hemoglobin level because of the lifespan of 
erythrocytes (> 100 days) and is therefore still undetectable on day 18 of leukemia. 
Nitrous oxide is not capable of reversing the process described above but the 
significant reduction of leukemic growth also results in reduced leukemic infiltration 
of the bone marrow. Especially the more mature precursors, only capable of in vitro 
cluster formation, are spared as they are situated towards the centre of the femur 
(15). From all peripheral blood and bone marrow parameters studied it can be 
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concluded that nitrous oxide selectively decreases leukemic proliferation with little 
suppression of normal hemopoiesis in the BN rat. 
Possibly BN rats are by chance relatively unsensitive towards the hematological 
effects of nitrous oxide, but a marked strain dependency in rats has been described 
(16). Still, the BNML has proven to be a good model for the chemotherapeutic 
response of human acute myeloid leukemia. As human hematopoiesis is more 
vulnerable to cobalamin inactivation than rat hematopoiesis (17) this might also imply 
a greater sensitivity of human leukemia for the effects of nitrous oxide. In vitro 
studies (18) have shown that the folate-dependent dTMP synthesis in cells of allmost 
all types of human leukemia can be disturbed by exposure to nitrous oxide. However 
only nitrous oxide exposure of leukemia patients will provide the clinical evidence for 
a possible differential effect on normal and and malignant hemopoiesis in humans. In 
anesthesia nitrous oxide is considered to be a very safe agent without any other 
known side effects. Since the preliminary reports on leukemia treatment with this gas 
(6,7), the biochemical knowledge concerning the interference of nitrous oxide and 
cellular proliferation has extended enormously. Nowadays the effects of nitrous 
oxide-induced cobalamin inactivation on hemopoiesis can be monitored easily (3). 
Moreover, eventually induced bone marrow depression can be reversed by the 
treatment with folinic acid (19), a folate form which is capable to replenish 
intracellular reduced folate pools independently of methionine synthetase activity. The 
clinical application of nitrous oxide in the treatment of hematological malignancies 
therefore deserves renewed attention. 
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Chapter 3 
Toxicity of methotrexate in rats preexpo-
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3.1. Summary. 
Several chemotherapeutic protocols for the treatment of malignancies include 
administration of methotrexate (MTX) during or shortly after total anesthesia. 
Clinical observations in patients treated for breast carcinoma or childhood cancer 
have shown unexpected myelosuppression and mucosal damage. This phenomenon 
may be attributed to the synergistic effects of nitrous oxide (N20), inactivating the 
cobalamin coenzyme of methionine synthase, and MTX, inhibiting dihydrofolate 
reductase, on folate metabolism. However, no quantitative data on dose/effect 
relationships are available regarding the combined toxicity of MTX and N 20. We 
investigated the effect of exposure to N20 on the toxicity of MTX. Groups of male 
Wistar rats were exposed to either 50% N20/50% 0 2 or air for 12 - 48 hours. 
Subsequently, a single i.p. injection of 10, 20, 40 or 80 mg MTX per kg body weight 
was given. Gastrointestinal toxicity resulted in diarrhoea and weight loss in all groups 
during 5 days after MTX administration. Concomitantly, bone marrow depression with 
leucocytopenia and thrombocytopenia occurred. Exposure to N20 did not alter the 
plasma clearance of MTX. No substantial liver or kidney toxicity could be detected. 
Still, the lD50 for MTX was reduced from 60 mgjkg to 10 mgfkg if rats had been 
exposed to N20 for 48 hours, the main causes of death being dehydration and 
bleedings. The administration of 5-formyltetrahydrofolate (4x10 mg,i.p.) but not 
5-methyltetrahydrofolate protected against the lethal effect of the drug combination. 
Altogether, cytotoxic effects of MTX on proliferating cells are potentiated by N20. 
Therefore, the use of this anesthetic shortly before or during MTX administration has 
to be avoided. 
4.2. Introduction. 
The folate antagonist methotrexate (MTX) has become a widely used antimetabolite 
in cancer chemotherapy (1,2). The drug is a potent inhibitor of dihydrofolate 
reductase. It is subject to intracellular polyglutamation which results in increased 
cellular retention and higher affinity for other folatedependent enzymes (3). 
Subsequent severe disturbance of folate metabolism, accompanied by a decrease of 
cellular reduced folate compounds which are required for thymidylate ( dTMP) and 
purine biosynthesis, is considered to be the backbone of MTX interference with DNA 
replication. 
Not surprisingly common side effects of MTX treatment are myelosuppression and 
gastrointestinal toxicity. Renal and liver damage may occur as well, in particular after 
high dose and/or chronic administration of MTX (1,2). Combination of MTX with 
several other drugs has proven to increase the therapeutic efficiency and/ or the 
toxicity in vitro and in vivo (1,2,4). The clinical significance of many of these 
interactions remains to be determined ( 4). 
Observations in patients treated for metastatic breast carcinoma (5,6) or childhood 
leukemia (7) have shown that ordinary MTX administration during or shortly after 
N20 anesthesia may provoke severe symptoms of which bone marrow depression and 
gastrointestinal toxicity are the most pronounced. This may be explained by the fact 
that the anaesthetic gas N20 inactivates the cobalamin coenzyme of methyl-
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tetrahydrofolate homocysteine methyltransferase or methionine synthase 
(E.C.2.1.1.13). Since the discovery of this effect of N20 on cobalamin, many studies 
have been performed to elucidate the consequences of prolonged exposure to N20 on 
cellular folate metabolism.' These data were recently reviewed (8,9). Methionine 
synthase appears to be essential for the cellular retention of reduced folates because 
methyltetrahydrofolate (5-methylTHF), the major extracellular folate, has to be 
demethylated to THF, before it can be polyglutamated and converted to the other 
active coenzyme forms .. Prolonged exposure to N20 therefore leads to depletion of 
cellular folates by loss of 5-methylTHF and severe disturbance of folate-dependent 
methylation reactions such as the de novo synthesis of dTMP. Regarding the specific 
biochemical lesions of MTX and N20 it is not surprising that both agents, through 
inhibition of different metabolic pathways of folate mutually potentiate their effects 
on the DNA synthesis of proliferating cells. In vitro studies on human normal bone 
marrow have proven a synergistic effect of MTX and N20 on nucleotide synthesis 
(10). Both in lymphoblast cell lines (11) and in a rat model for myeloid leukemia 
(12), exposure to N20 increased the sensitivity of proliferating leukemic cells for 
MTX. Still, no experimental data exist on the toxicological consequences of the 
N20-MTX interaction. In the present study we investigated the potentiation of MTX 
by N20 and the impact of this combination on the tissues which are most vulnerable 
for MTX toxicity. 
4.3. Materials and methods. 
Animals.. Male rats of the Wistar inbred strain were used, at the age of 12 - 16 weeks 
(200-250 g). Food and water were supplied ad libitum during all experiments. 
Materials. Both sodium Methotrexate and calcium 5-formylTHF were obtained from 
Lederle (Etten-Leur, The Netherlands). N20 used in the studies was obtained from 
Hoekloos (Schiedam, The Netherlands). 5-MethylTHF was obtained from Sigma (St 
Louis, USA). 
Exposure of rats to N20. Rats were placed in a 40 L flow chamber through which a 
gas mixture of 50% N20/50% oxygen was blown at a rate of 800 mljmin. Moreover, 
excess carbon dioxide, water and contaminating volatile compounds were eliminated 
in a cleaning circuit (13). Oxygen concentration was monitored with an oxygen 
analyser (Teledyne Analytical Instruments). In one experiment various amounts of 
N20 (0%-50%), replenished by nitrogen (50%-0%) and 50 % oxygen were used to 
study the effect of the inhaled N20 concentration on MTX toxicity. Rats not exposed 
to N20 were kept in air but otherwise treated identically. 
W 50 study. Groups of 25 rats were exposed to N20 for 12, 24 or 48 hours or to air. 
Directly thereafter each group was divided in 5 clusters of 5 rats which received an 
i.p. injection of 1 ml MTX solution in 0,9% NaCl, resulting in a dose of 0 (controls), 
10, 20, 40 or 80 mg MTX per kg body weight. Subsequently, they were kept in normal 
housing conditions for 3 weeks and body weight and number of deaths were checked 
daily. 
Persistence of N20 induced effects on MTX toxicity. For this experiment 25 rats were 
exposed to N20 for 48 hrs. Subsequently groups of 5 rats received 40 mg MTX/ kg 0, 
6, 12, 24, and 48 hrs after termination of N20 exposure. Rats were observed for 3 
40 
weeks. 
Clearance of MTX. The plasma MTX clearance following i.p. injection of 20 mg MTX 
per kg body weight was monitored in 2 groups of 5 rats, one of which had been 
exposed to N20 for 48 hours. Rats were anesthetized mildly by ether inhalation when 
blood (0,8 ml) was sampled by orbita plexus puncture to determine plasma 
concentrations of MTX and 7-hydro:xymethotrexate (7-0H- MTX) as described before 
(14). 
Evaluation of gastrointestinal toxicity. Gastrointestinal tract toxicity was assessed on the 
basis of body weight and the occurrence of diarrhoea in rats used for determination 
of l.D50 values. The gastrointestinal tract of rats sacrificed for evaluation of 
hematological, liver and kidney toxicity, was also inspected macroscopically. 
Evaluation of hematological toxicity. In the first experiment 2 groups of 5 rats, of which 
one had been exposed to N20 for 48 hrs., were i.p. injected with 10 mg MTX/kg body 
weight. At day 1, 4, 7, 13 and 21 after MTX, 0,8 ml blood was collected by orbita 
plexus puncture. Leucocyte count and hemoglobin concentration were determined 
with a Sysmex Cellcounter cc-120. Thrombocytes were counted with the Platelet 
Analyser 800 (Baker). Bone marrow toxicity was investigated in a second experiment. 
Rats were exsanguinated directly or 48 hrs or 96 hrs after (NP-)MTX administration 
(10 mg per kg body weight). The femurs were flushed with 10 ml Alpha medium 
containing 0,1% fetal calf serum. The collected bone marrow cells were washed, and 
lOS cells were plated in triplicate in methylcellulose cultures for assessment of Colony 
Forming Unit-Fibroblast (CFU-F) (15) and Colony Forming Unit-Granulo-
cyte/Macrophage (CFU-GM) (16). 
Evaluation of hepatotoxicity and renal toxicity. EDTA plasma, already sampled for 
other purposes, was also used for determination of alanine aminotransferase (ALAT) 
and aspartate aminotransferase (ASAT) on an ACP 5040 (Eppendorf), of fibrinogen, 
according to Claus et al. (17) on a coagulometer (Amelung), of plasma total protein 
by the biuret assay and of creatinine and urea on a R.A1000 (Technicon). 
Rescue study. Three groups of rats were exposed to N20 for 48 hrs and injected with 
40 mg MTX/kg. One group received no further treatment, a second group received 4 
x 10 mg 5-methylTHF /kg every 12 hrs starting 24 hrs after MTX, and a third group 
received 4 x 10 mg 5-formylTHF in a similar schedule. Toxic deaths were recorded 
during 3 weeks thereafter. 
Statistical analysis.. The Mann-Whitney U-test was used to evaluate significance of 
observed differences among treatment groups. 
4.4. Results. 
LD50 study. In order to quantify the interaction of N20 with MTX, a matrix of 
combinations of both agents was administered to groups of 5 rats. Table 3.1 shows 
that 12 hours of N20 exposure induced lethal toxicity when combined with 40 mg 
MTX per kg body weight. NP preexposure of 24 or 48 hrs resulted in an increased 
lethality of all MTX dosages. Animals usually died between 6 and 10 days after MTX 
administration; Interpolation of combined data resulted in a LD50 for i.p. MTX of 60 
mg per kg body weight. In combination with prior exposure to N20 for 48 hrs the 
LD50 of MTX became approximately 10 mgjper kg body weight. 
Table 3.1: 
Toxicity of i.p. MTX after N20 exposure in rats 
N20 preexposure (in hrs) 
0 12 24 48 
0 0 0 0 0 
O> 
10 0 0 2 ..><:: 0 
...... 
Ol 
E 20 0 0 3 c 
= p 40 0 2 4 
:2 
80 4 5 N.D. N.D. 
Clusters of 5 rats were exposed to NP for various periods prior to i.p. MTX (0-80 mg/kg). 
The number of toxic deaths in each cluster are shown. 
Table 3.2: 
Effect of various N20 concentrations on MTX toxicity. 
Composition of inhaled gas mixture (% v) n toxic deaths 
N20 02 N2 
0 20 80 5 0 
0 50 50 5 0 
5 50 45 5 0 
10 50 40 5 1 
25 50 25 5 1 
50 50 0 5 3 
Rats were exposed to gas mixtures containing 0 - 50 % N20 for 48 hrs. Subsequently 
they received i.p. 20 MTX/kg. The number toxic deaths are shown. 
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Effect of various N20 concentrations on MTX toxicity. Toxicity 20 mg MTX/kg in 
combination with 48 hrs exposure to several NP concentrations was studied. Table 
3.2 shows that already 10 % N20 increases the lethal toxicity of MTX. Table 3.2 also 
reveals that 50% oxygen by itself (in combination with 50% nitrogen) does not 
enhance MTX toxicity. 
Exposure to N20 after MTX administration. Table 3.3 demonstrates that MTX toxicity 
is substantially less when N20 exposure follows than when it precedes MTX (see also 
table 3.1). 
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Table 3.3: 
Toxicity of i.p. MTX followed by N20 exposure for 48 hours. 
Treatment n toxic deaths 
10 mg MTX 4 0 
10 mg MTX + 2 days Np 5 0 
20 mg MTX 4 0 
20 mg MTX + 2 days NP 5 
Table 3.4: 
Toxicity of i.p. MTX (40 mg per kg) administrated directly, 
6, 12, 24 of 48 hrs after 48 hrs N20 exposure. 
Interval between N20 exposure n toxic deaths 
and MTX administration 
0 5 5 
6 hrs 5 5 
12 hrs 5 3 
24 hrs 5 2 
48 hrs 5 0 
Persistence of NP induced effect on MTX toxicity. Table 3.4 demonstrates that 
exposure to N20 for 48 hours prior to i.p. 40 mg MTX/kg, leading to 100 percent 
morbidity when MTX is given directly after N20 exposure, becomes less toxic when 
the interval between N20 and MTX is prolonged to more than 6 hours. 
MTX clearance. The plasma clearance of MTX was studied after 48 hrs exposure to 
N20. Figure 3.1 Tabl 
reveals that elimination of the drug from the systemic circulation does not change by 
exposure to N20. Only trace amounts of 7- OH-MTX, the major metabolite of MTX, 
were detected in plasma of both treatment groups. 
Gastrointestinal toxicity. The physical condition of all rats used for the LD50 
determinations was checked daily. Usually the first sign of toxicity was loss of body 
weight followed by diarrhoea and bleeding from the nose. If the weight loss had not 
been regained withm 5 days after MTX administration, death usually followed within 
a few days. In figure 3.2 the average body weight per group on day 5 after MTX are 
expressed as the percentage of the body weight on the day of MTX administration. 
As the rats were only 12 weeks old, absence of toxicity resulted in increased body 
weight (approximately 15% in 5 days). Macroscopical dissection of rats after death 
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Figure 3.1: Plasma clearance of MTX (20 mg/kg i.p.) in control rats (o) and in rats exposed to N20 for 48 
hrs (•). Values are the mean ± s.d. of 5 rats. 
revealed extensive bleeding from ulcerations throughout the gastrointestinal tract of 
rats suffering from diarrhoea. N20 alone had no noticeable effect on body weight 
(data not shown). 
Hematological toxicity. In figure 33 the effect of 10 mg MTX/kg with or without 
exposure to NP (48 hrs) on the number of peripheral leucocytes and platelets are 
presented. Both numbers are suppressed when MTX is preceded by N20 and reached 
a nadir approximately 7 days after MTX administration. MTX alone also induced a 
decrease in the leucocyte count, but 7 days later. The hemoglobin concentration of 
peripheral blood in the combination treatment group had increased 15% on day 4 
after MTX but returned to 10% below normal afterwards (data not shown). In the 
N20-MTX group 2 rats died at day 8 and 9 respectively, so data from day 14 and 21 
are the average of 3 rats. 
As granulocytes and monocytes make up only 10 percent of peripheralleucocytes in 
rats, clonogenic assays were performed to investigate the impact of N20-MTX on 
myelopoiesis. Stromal integrity was measured by culturing fibroblast colony forming 
cells (CFU-F). Figure 3.4B reveals that both MTX and N20-MTX cause a reduction 
of CFU-GM in bone marrow. However, recovery after MTX alone is much faster 
than after preexposure to N20 as is clear from total marrow cellularity (figure 3.4A) 
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Figure 3.2: Effect of exposure to N20 prior to i.p. MTX on body weight of clusters of 5 rats, 5 days after 
MTX administration. Np exposure time and MTX dosage were variable. Mean body weight of each 
cluster is expressed as a percentage of the weight just before MTX administration. All bars < 100% were 
statistically different from the control bars (p < 0.05). 
and the amount CFU-GM present in bone marrow at day 4. Cytotoxic effect of N20-
MTX on CFU-F (figure 3.4C) is maximal after 4 days, but by this time bone marrow 
stroma in MTX treated rats has already recovered. 
Exposure to N20 for 48 hrs alone causes no changes in the studied parameters 
afterwards (data not shown). 
Hepatotoxicity and renal toxicity. Table 3.5 presents a panel of plasma factors 
determined to assess hepatic and renal toxicity, 96 hrs after MTX administration 
when the animals are suffering maximally from induced toxicity. There was no 
evidence of specific damage to liver or kidneys. Exposure to N20 for 48 hrs alone 
causes no changes in the studied parameters afterwards (data not shown). 
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Figure 3.3: Peripheral leucocyte and platelet counts in MTX treated rats (10 mg/kg) with ( •) or without 
(o) 48 hrs preexposure to N20. Values are means ± s.d. of 5 rats. 
Table 3.5: 
Effect of N20-MTX on several parameters, indicative for hepatic and renal toxicity. 
Treatment n ASAT(u/1) ALAT(U/L) Fibrinogen Plasma total Plasma urea Plasma 
(g/L) protein (g/L) (mmoi!L) creatine 
(fliTlOI/l) 
Controls 5 43±5 33±2 1.6 ± 0.1 64±3 7.8 ±0.7 53 ±3 
Np 5 40±2 43± 12 1.6 ± 0.1 64±2 7.1 ± 1.1 47±3 
10 mg MTX/kg 4 57± 10 39±3 * 1.7 ± 0.1 71 ±2* 8.7 ± 0.9 69 ± 10* 
Np + 1 0 mg MTX/kg 5 47±5 25 ±5 * 1.6 ± 0.2 61 ±4 6.0 ± 0.7** 42± 12 
Rats, either or not exposed to 48 hrs Np, received 1 0 mg MTX/kg i.p .. After 4 days rats were sacrificed and plasma 
collected for determination of listed parameters. Values are means± s.d., *: p < 0.05, **: p < O.D1. 
Rescue study. Table 3.6 reveals that 5-formylTHF administered 4 times over a period 
of 48 hrs is able to prevent the lethal toxicity of 48 hours N20 in combination with 40 
mg MTX/kg. However with 5-methylTHF, administered in a similar schedule, only 2 
of the 4 animals survived. 
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Figure 3.4: Effect of MTX (10 mg/kg) on bone marrow of rats either or not pretreated with 48 hrs Np. 
Values for total femorai cell count, myeloid progenitors (CFU-GM) and fibroblast progenitors (CFU-F) 
(mean ± s.d.). Open bars: controls, spickled bars: N20 exposed. All differences between controls and N20 
treated groups at 48 hrs and % hrs are statistically significant (p<0.05). 
Table 3.6: 
Rescue efficiency of 57formyiTHF and 5-methyiTHF for N20-MTX 
induced toxicity. 
Treatment n toxic deaths 
40 mg MTX 5 0 
2 days NP + 40 mg MTX 5 4 
2 days NP + 40 mg MTX + 5-FORMYL THF 4 0 
2 days Np + 40 mg MTX + 5-METHYL THF 4 2 
Rats were treated with 48 hrs N20 and 40 mg MTX/kg. After 24 hrs one group 
received 4 x 10 mg/kg leucovorin and another group received 4 x 1 0 mg/kg 
5-methyiTHF. Rats were observed and toxic deaths recorded. 
3.5. Discussion. 
47 
Possible mechanism. The present study provides experimental evidence that N20 
potentiates the toxic effects MTX on normal proliferating cells in vivo whereas the 
plasma clearance of MTX remains unchanged. Exposure to N20 before administration 
of MTX is a prerequisite for synergism because NP treatment after injection of the 
antifolate does not cause increased toxicity. The possibility that the increase in lethal 
toxicity of MTX is caused by the elevated oxygen concentration (50%) can be 
excluded on both experimental (see table 3.2) and literature data (18,19). 
The potentiation of MTX toxicity by the various periods of NP exposure closely 
follows the intracellular changes occurring during cobalamin inactivation. 12 Hrs of 
N20 exposure increases lethal toxicity of MTX. Studies in rats have shown that after 
N20 exposures of this duration, methionine synthase activity is completely suppressed 
and the conversion of 5-methylTHF to other reduced folates, necessary for various 
coenzym functions in thymidylate and purine synthesis, also is impaired (8,9). 
Prolonging the N20 exposure to 48 hrs results in further increase of lethality from 
MTX. These observations agree with those of Chanarin et al. (8,9) who demonstrated 
a massive depletion of rat tissue folates within 48 hours N20 (thereby increasing the 
sensitivity of proliferating cells for MTX). Moreover, increased activity of 
folylpolyglutamate synthase (9,20) as a consequence of the induced folate depletion, 
may result in enhanced polyglutamation of the drug (20,21), which enhances its 
cytotoxicity. 
Already 10 % N20 in the inhaled gas mixture is sufficient to increase the lethal 
toxicity of MTX. This is in agreement with Kondo et al.(22) who showed that 
inhibition of methionine synthase already occurs during exposure to 2% N20. 
Although complete recovery of methionine synthase activity from N20 exposure and 
subsequent repletion of tissue folates require several days (22, 23), the mortality from 
48 hrs N20 plus 40 mg MTX/kg decreases rapidly if MTX administration is 
postponed. This suggests that partial restoration of methionine synthase activity is 
already sufficient to prevent the synergistic interaction between N20 and MTX. 
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Spedfic organ toxicity. The effect of N20-MTX consists of cytotoxic action towards the 
rapidly dividing cells of mucosa and bone marrow. Little is known about the effect of 
N20 exposure alone on the mucosa although inactivation of methionine synthase and 
reduced uptake of dietary folates (without diarrhoea) have been demonstrated (24). 
Combination of non-lethal dosages N20 and MTX causes lifethreatening loss of body 
weight by diarrhoea induced dehydration and reduced food intake by the sick animals. 
Effects of N20-MTX on hematopoiesis also show synergistic features. Bone marrow 
depression and pancytopenia in N20 pretreated rats is more pronounced and the 
recovery of myelopoiesis is delayed. N20-MTX effects on stromal elements, which are 
considered to be essential for hematopoiesis, increases up to 4 days suggesting cyto-
toxic activity towards pre-CFU-F cells and may contribute to the sustained bone 
marrow depression. N20 alone induces an increase of the myeloid progenitors. This 
agrees with earlier observations in rats in which N20 induced accumulation of the 
myeloid precursors in the bone marrow (25). 
It has been suggested that the hepatotoxicity of chronic MTX administration may 
be related to a reduction of folate-dependent methionine synthesis as this causes 
hepatic depletion of choline, the necessary precursor for the alternative, 
betaine-dependent methionine synthesis (26,27). However, N20-induced inhibition of 
methionine synthase does not provoke acute liver toxicity from MTX treatment as is 
clear from the data presented in table 3.5. This is probably related to the minor 
importance of the thymidylate synthase/ dihydrofolatereductase pathway for the 
restoration of TIIF pools in the non-dividing cells of the liver (28). 
Clinical implications and perspectives. For this study rats were chosen as test animal as 
substantial knowledge is available on both N20 and MTX effects on folate 
metabolism in rats. Moreover the biochemical events of N20 exposure in the rat 
closely resemble those in man (9) although the latter is known to be more vulnerable 
towards N20 effects on cell proliferation (29). Comparison of the presented data and 
reported clinical observations in breast cancer patients (5,6) reveals some striking 
similarities. The incidence of unpredictable side effects after postoperative 
chemotherapy (including MTX) was inversely correlated with the period between N20 
anesthesia and MTX administration. Toxicity could be alleviated with 5-formylTIIF, 
although the effect of this rescue therapy on the efficiency of the employed 
chemotherapeutic protocol is not yet known. 
In our study, 5-formylTIIF was also efficient as rescue agent. However, the exact 
mechanism by which this drug restores the intracellular reduced folate pool is still 
subject of dispute. In vivo this rescue agent is rapidly converted to 5-methylTHF (30) 
and several studies have revealed that the latter may also play an important role in 
reversal of MTX toxicity (31,32). In N20 treated subjects however, only unmetabolised 
5-formylTIIF is capable of entering the cellular reduced folate pools (11,33). As 
conversion of 5-formylTHF to 5-methylTIIF differs considerably among the various 
routes of administration (34), differences in rescue efficiency in case of N20-MTX 
toxicity may be expected. 
Recently it has been suggested that N20 reduces the antineoplastic effects of MTX 
as a consequence of induced toxicity (7). However, Kroes et al (12) have already 
demonstrated the chemotherapeutic benefit of MTX when combined with N20 
exposure in a rat model for myeloid leukemia. Moreover, it is shown that the 
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deleterious effects of MTX on folate metabolism of fresh human leukemic cells could 
be significantly enhanced by NP (35) implicating a possible antineoplastic synergism 
of both drugs as has been suggested before (10). 
Conclusion. Exposure to N20 prior to MTX administration results in a dosedependent 
synergistic cytotoxicity towards the proliferating cells of mucosa and bone marrow. 
The biochemical mechanism through which the synergism between N20 and MTX 
occurs is not yet fully understood but is related to the inhibition of 2 important 
enzymes in the formation of reduced folates, necessary for both purine and dTMP 
synthesis. Effective alleviation from resulting toxicity can be achieved by intravenous 
5- formylTHF administration. However the demonstrated synergistic action of the 
anesthetic gas N20 and MTX on dividing cells merits further investigation of its 
possible applicability in the treatment of neoplastic diseases. 
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4.1. Summary. 
Exposure to nitrous oxide inactivates the cobalamin coenzyme of methionine 
synthetase, an essential enzyme in folate metabolism. Hemopoietic cells are especially 
dependent on the function of cobalamin for the folate-dependent synthesis of 
thymidilate ( dTMP). Inhibition of methionine synthetase may therefore be of 
potential value in the treatment of hematological malignancies. In the present study 
we investigated the effect of nitrous oxide induced cobalamin inactivation on folate 
metabolism of fresh leukemic cells and the human myelomonocytic cell line U937. 
Cells were exposed to nitrous oxide for 20 hours. Subsequently they were subjected to 
the deoxyuridine suppression test (dU test), which measures the disturbance of folate-
dependent dTMP synthesis. In all bone marrow samples, cobalamin inactivation 
resulted in a 200% increase of the dU test value, implicating a decreased de novo 
synthesis of dTMP. Incubation of leukemic cells with methotrexate, 5-fluorouracil or 
cycloleucine induced similar increases of the dU test values which could be further 
raised to 400% with the addition of N20 exposure. Prolonged experiments with U937 
cells revealed that the disturbance of folate metabolism aggravated up to 48 hours of 
nitrous oxide exposure. It can be concluded that cobalamin inactivation in human 
leukemic cells results in disturbed folate-dependent dTMP synthesis. Moreover, 
effects of several drugs interfering with folate metabolism can be enhanced. 
4.2. Introduction. 
Cobalamin, or vitamin B120 is a nutritional factor indispensable for the maintenance of 
normal hematopoiesis. This is explained by its role as a coenzyme in methionine 
synthetase, or 5-methyltetrahydrofolate homocysteine methyltransferase, the enzyme 
which is essential for the intracellular conversion of reduced folates into forms that 
can be retained in the celL Several steps in the biosynthesis of nucleotides require the 
presence of folate coenzymes. In particular the de novo synthesis of thymidylate 
( dTMP) from uridylate (dUMP) appears to be sensitive to reduced availability of the 
necessary coenzyme 5,10- methylene tetrahydrofolate (See figure 4.1). As dTMP is an 
indispensable precursor for DNA synthesis, this provides the link between cobalamin 
deficiency and a disturbance of hematopoietic proliferation. 
This immediate importance to proliferating cells makes the metabolism of reduced 
folates a potential target in the chemotherapy of malignant tumors. Structural 
analogues of reduced folates, notably methotrexate (MTX), have demonstrated the 
validity of this approach. Attempts have been made to find similar antagonists of the 
essential coenzyme function of cobalamin in methionine synthethase. However early 
efforts, mainly with structural analogues, were largely unsuccessful (1-3). No effective 
antagonist of cobalamin was known until the recognition of a peculiar side effect of 
the anesthetic gas nitrous oxide (N20) in 1978 (4), which already was known to cause 
megaloblastic hematopoiesis on prolonged exposure (5). N20 inactivates the 
cobalamin coenzyme of methionine synthetase (7) by oxidation of its cobalt(!) moiety. 
This particular reaction results in a virtually complete and irreversible inhibition of 
this enzyme ( 6). The availability of a genuine cobalamin antagonist has revived the 
interest in possible applications in chemotherapy. 
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Figure 4.1: Outline of the most important intracellular interconversions of reduced folates and the 
principal biochemical targets of the drugs nsed in this study. 
In addition, the demonstration of the cobalamin dependence of malignant 
proliferation is of more general interest. We have shown previously that nitrous oxide 
reduces the growth of leukemia in rats (8), and renders the leukemic rats more 
susceptible to subsequent therapy of several drugs interfering with other pathways of 
folate metabolism (see figure 4.1) (9,10,11). Kano et al. (12) have demonstrated that 
NP inhibits nucleotide synthesis and proliferation in a number of human 
hematopoietic cell lines. 
In this study, we have investigated the in vitro effects of N20 on human leukemic 
cells derived from patients with different types of acute leukemia and the 
myelomonoblastic cell line U937 (13). Moreover combination of cobalamin 
inactivation with MTX, 5-FU and cycloleucine, an effective inhibitor of methionine 
adenosyltransferase (14), was studied. The assessment of the sensitivity of human 
leukemia to N20 should be considered an essential step towards the application of 
cobalamin inactivation in clinical chemotherapy. The deoxyuridine suppression test, 
being an established method to demonstrate the metabolic consequences of 
cobalamin deficiency or inactivation, was used to evaluate the effects of nitrous oxide. 
4.3. Materials and methods. 
Leukemic bone marrow and blood cells. Bone marrow aspirates and peripheral blood 
samples were obtained from consenting patients with a diagnosis of acute leukemia. 
The patients were untreated, or, in some cases, in early relapse of their disease. Each 
marrow aspirate, usually 1-3 ml, was collected in a sterile bottle containing 0.4 ml 
(2000 IU) heparin. Peripheral blood was collected in heparinized tubes. Each case of 
acute myeloid leukemia (AML) was morphologically and cytochemically classified 
according to the FAB clas sification (15,16), and cases of acute lymphoid leukemia 
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(ALL) were classified according to immunological phenotype. The percentage of 
leukemic blasts in each bone marrow sample was determined in a differential count 
of 500 cells. 
Isolation of nucleated cells from marrow and blood. Bone marrow aspirates and 
peripheral blood samples were diluted with an equal volume of Hanks' balanced salt 
solution and gently admixed with 0,5 ml methylcellulose solution (2%wjv) to promote 
rouleaux formation. After 10 minutes, the red cells were sedimented and nucleated 
cells could be isolated from the supernatant. The cells were washed in Hanks' 
balanced salt solution, counted and diluted to a concentration of 106/ml with McCoy's 
medium SA with 10% Fetal Calf Serum. Folic acid (pteroylglutamic acid) was 
replaced by 400 nmol/1 methyltetrahydrofolate (Sigma, St.Louis, USA), and 
methionine was limited to 25 mmoljl, as these constituents have to be carefully 
controlled in studies on cobalamin and folic acid metabolism. Viability of the cells 
was checked by trypan blue exclusion. 
Culture of the ceH line U93Z The myelomonoblastic cell line was cultured in 
suspension, in specially prepared McCoy's medium SA similar to the one descibed 
above. Experimental conditions were as described by Kano et al., with 200 nmol/1 of 
5-methyltetrahydrofolate (10) and were carried out with cells in a logarithmic growth 
phase. Exposure to nitrous oxide and subsequent incubations were performed as 
described for bone marrow cells. 
Exposure of cells to nitrous oxide. Cell suspensions (5 ml in flasks of 50 ml) were 
exposed to nitrous oxide by gassing the culture flasks during 30 min with a filtered 
mixture of 50% nitrous oxide, 20% oxygen, 25% nitrogen and 5% carbon dioxide, 
released from a premixed cylinder (Hoekloos, Schiedam, The Netherlands). After this 
period, the flasks were closed and incubated overnight for about 20 h at 37 oc. 
Control suspensions were exposed to a mixture of air with 5% carbon dioxide, and 
otherwise treated identically. After incubation, viability was checked again by trypan 
blue exclusion and the cells were directly subjected to the dU test. 
Addition of drugs. H enough cells were available, MTX (final concentration 5.10-a 
mol/L, Ledertrexate), 5-FU ( final concentration 5.10-6 mol/L, Hoffmann LaRoche) 
or cycloleucine (final concentration 10·3 mol/L, Sigma) were added to the cell 
suspensions at the start of the exposure to the gas mixtures and remained there 
during the whole incubation period. 
Deoxyuridine suppression test This test was used to evaluate the impairment of the de 
novo synthesis of thymidylate as a consequence of the disturbance of folate 
metabolism. fH]-Thymidine incorporation into DNA is measured with and without 
the pre-incubation of cells with deoxyuridine. Deoxyuridine suppresses the 
incorporation of fH]-thymidine if it can be converted to thymidylate by 
folate-dependent methylation. H this conversion is impaired, the suppression by 
deoxyuridine will be reduced. The results of this assay are expressed as the 
percentage ratio of the fH]-thymidine incorporation with and without deoxyuridine in 
similar cell suspensions. The test was carried out essentially as described by Metz et 
al. (17), with some modifications. Briefly 106 cells in 1 ml Hanks' balanced salt 
solution with or without 0,1 mmol/L dU were incubated for 2 hours at 37 °C, 
followed by another 2 hour incubation in the presence of 0,3 JLCi fH]-thymidine 
(specific activity: 25 Ci/mmol, Amersham, UK). All results were the mean of triple 
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incubations. 
Statistical Analysis. Data were statistically evaluated with the Wilcoxon's signed- ranks 
test for 2 groups. 
4.4. Results. 
Patient chamcteristics. 18 patients were involved in this study and their characteristics 
are summarized in table 4.1. The mean blast count of the blood samples was 63 ± 
22%, the bone marrow cell fractions contained 70 ± 25% leukemic blasts. 
Table 4.1: 
Characteristics of leukemia patient samples used 
for in vitro cobalamin inactivation. 
Number of patients involved 
Male 
Female 
Diagnosis 
Acute myeloid leukemia 
Acute lymphoid leukemia 
Leukemic transformed M.D.S. 
Studied material 
Bone marrow aspirates 
Peripheral blood 
18 
11 
7 
12 
4 
2 
16 
9 
Effect of cobalamin inactivation on fresh leukemic samples.. The results of deoxyuridine 
suppression tests after nitrous oxide exposure of leukemic marrow cells, compared to 
the same cells exposed to air, are shown in table 4.2. In all cases, the exposure to 
nitrous oxide caused a marked increase of the test value, indicating an impaired 
ability to use dUMP as a substrate in the de novo synthesis of dTMP. In normal 
healthy bone marrow the percentage suppression by dU varies but usually the upper 
level of the normal range is considered to be 10%. The variation of suppression 
values after exposure to air, from 3 to 15% in our study, with a mean of 9%, is 
probably related to the heterogeneity of cell types in different forms of leukemia and 
the patients physical condition. DU tests of leukemic bone marrow performed directly 
after the aspiration show a similar degree of variation (data not shown). After nitrous 
oxide exposure of cells derived from the same bone marrow samples, the test values 
range from 8 to 57%, with a mean of 21% (significance: p<0.01). Results obtained 
with blood cells from 9 leukemia patients, are also presented in table 4.2. The 
increase in mean suppression values, from 8 to 14%, is comparable to the result 
obtained with the marrow cells. However this time the pattern is somewhat less 
consistent as 2 of the 9 samples were found to be unresponsive to nitrous oxide, both 
from cases of ALL. 
Effect of N 20 with concomitant erposwe to other drugs. Methotrexate was added, prior 
to the incubation, to 6 of the leukemic marrow cell suspensions and 2 peripheral 
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Table 4.2: 
Effect of 1\120 exposure (20h) on the dU suppression value of 
leukemic cells derived from bone marrow and peripheral 
blood (mean ± s.d.). 
Origin of cells 
Bone marrow 
Peripheral blood 
Table 4.3: 
n 
16 
9 
dU test values 
air 
9,0 ±3,8% 
7,5 ±4,5% 
21,4 ± 13,2% 
13,4 ± 8,1% 
Effect of several drugs and the concomitant exposure to N20 (20 h) on 
the dU suppression value of leukemic bone marrow cells (mean ± s.d.). 
n air i\120 MTX (5.10-8M) i\120+MTX 
6 10,5 ± 3,0% 22,0 ± 10,1% 38,9 ± 17,2% 49,5 ± 12,2% 
n air i\120 5-FU (5.1 o-s M) i\120+5-FU 
7 7,4 ± 4,2 21,1 ± 15,8% 34,7 ± 22,1% 46,3 ± 22,6% 
n air i\120 cycloleucine (1 o-3 M) i\120 + cycloleucine 
5 7,9 ± 3,7% 20,5 ± 4,7% 9,5 ± 2,1% 27,9 ± 4,2% 
blood cell suspensions. The results are shown in table 4.3 and 4.4 respectively. The 
addition of methotrexate alone to the marrow cells increased the suppression value in 
all cases, from a mean of 11% to a mean value of 39%. If the cells were, in addition, 
exposed to N20, this resulted in a significant, further increase of the mean 
suppression value to 50% (p < 0.05). In some cases, however, in which methotrexate 
was already very effective, no substantial further increase was observed; this applies to 
values of 60% and higher. It should be emphasized that these values indicate a rather 
extreme disturbance of the folate metabolism. Therefore it is possible that 
aggrevation of tl,ris disturbance by cobalamin inactivation is not detectable anymore. 
The two peripheral samples, demonstrated a similar enhanced effect of methotrexate 
after concomitant exposure to N20. 
A comparable pattern was obtained with the combination of N20 with 5- FU (see 
table 4.3 and 4.4). Both blood samples and 6 of the 7 marrow samples showed an 
appreciable effect of 5-FU on the dU test value (mean 35%), which could be 
Table 4.4: 
Effect of several drugs and the concomitant exposure to N20 
on the dU suppression value of individual leukemic cell 
samples derived from peripheral blood. 
air N20 MTX N20+MTX 
8,6 8,5 24,4 29,5 
15,5 25,2 52,5 68,5 
air N20 5-FU N20+5-FU 
6,2 13,4 15,7 29,6 
13,5 21,5 25,2 36,4 
air N20 cycloleucine N20+cyclo 
7,1 13,6 5,5 27,4 
9,2 11,0 9,2 15,1 
Table 4.5: 
Effect of MTX or 5-FU and the concomitant exposure to N20 
for two days on the dU suppression value of U937 cells. 
treatment dayO day 1 day2 
air 12,1 14,2 12,6 
NP 12,1 16,3 24,2 
MTX (5.10-8 M) 12,1 18,4 50,5 
N20+ MTX 12,1 24,7 77,4 
air 5,8 13,7 12,6 
NP 5,8 12,1 11,1 
5-FU (5.10-6 M) 5,8 23,2 34,7 
Np+5-FU 5,8 28,4 51,6 
signifcantly aggrevated by N20 (mean 46%, p<O,OS). 
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Cycloleucine by itself did not affect the dU suppression value in most of the tested 
cases (mean 10%). In combination with N20 however a sharp increase was noted 
(mean 27%) in all bone marrow samples (p<O,OS) and the two peripheral blood 
samples (see table 4.3 and 4.4). 
Effects on the cell line U93Z Finally, results obtained with the cell line U937, with 
culture conditions as described by Kano et al. (12), are presented in table 4.5. 
Prolonged exposure to N20 with or without 5-FU or MTX up to 2 days resulted in a 
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time dependent increase of the dU suppression values. Consistently the cells exposed 
to the drugs in combination with N20 showed the largest increase of the dU test 
value. 
4.5. Discussion. 
At present, there is only limited evidence for the cobalamin- dependence of malignant 
hematopoiesis in human leukemia, which is an essential requirement for the possible 
application of cobalamin antagonists in chemotherapy. N20, the only available 
effective antagonist of the cobalamin coenzyme in methionine synthetase, has been 
shown to inhibit rat leukemia in vivo (8), and human leukemic cell lines in vitro (12). 
There are also two early observations of a distinct antileukemic effect of nitrous oxide 
exposure in patients (18,19), dating from the time before this agent was known to 
inactivate cobalamin. Moreover, two cases have been described of patients with 
leukemia, in which the administration of cobalamin was considered to have enhanced 
leukemic proliferation (20,21). 
A disturbance of the deoxyuridine suppression test in normal bone marrow cells 
after N20 exposure of about 24 hours is well established (22). The results of the 
present study provide evidence that in nearly all cases of acute leukemia the folate 
metabolism can also be disturbed by cobalamin inactivation, as is apparent from 
elevated values of the deoxyuridine suppression test. This in vitro metabolic effect of 
cobalamin inactivation on malignant blood cells is fully comparable to the 
consequences of cobalamin deficiency on normal marrow cells. It may therefore be 
expected that the application of nitrous oxide will result in the same inhibition of 
cellular proliferation as is observed in cobalamin deficient normal marrow cells. 
Combination of N20 with other drugs resulted in an enhanced disturbance of the 
folate metabolism. These observations are in accordance with a study in which the 
effect of N20 with MTX on normal bone marrow cells was examined (23). More 
interestingly our observations agree well with studies of the antileukemic activity of 
N20 combined with respectively cycloleucine, MTX, and 5-FU in the BNML. In this 
rat leukemia, which is considered to be a reliable model for human AML, the 
effective antiproliferative action of the three combinations mentioned above, was also 
reflected by severely disturbed dU test values (8-11). 
As nearly all cases of leukemia were responsive to cobalamin inactivation, it is 
difficult to draw conclusions on the differential sensitivity of particular types. It may 
be relevant, however, that all samples that were found to be unresponsive to N20 
were cases of ALL. 
With regard to the results obtained with the leukemic cell line U937, it can be 
concluded that the effects of cobalamin inactivation in combination with other drugs 
increase over substantial periods of time. This may possibly reflect the gradual 
changes in folate coenzyme pools induced by N20 (24,25), 5-FU (26) or MTX (27). 
In conclusion, the results of this study demonstrate that the metabolic consequences 
of cobalamin inactivation by nitrous oxide can be observed in malignant 
hematopoietic cells, as in normal marrow cells. The deoxyuridine suppression test may 
well be predictive for the clinical sensitivity of acute leukemias to N20, as results 
obtained with N20 in vitro are in agreement with those obtained by treating rat 
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leukemia in vivo. Moreover, these findings encourage further investigations, eventually 
directed at the administration of N20 to selected patients with leukemia. 
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Chapter 5 
Effect of nitrous oxide and methotrexate 
on folate coenzyme pools of blast cells 
from leukemia patients 
A.A.M. Ermens, M. Schoester, J. Lindemans and J. Abels. 
Submitted. 
5.1. Summary. 
The effects of methotrexate (inhibiting dihydrofolate reductase) and nitrous oxide 
(inactivating methionine synthase) on intracellular folate coenzyme levels of leukemic 
cells were studied. Blast cells from 10 cases of acute myeloid leukemia (AML) and 5 
cases of acute lymphoid leukemia (ALL) were incubated with 5x10-s M rHJ 
5-formyltetrahydrofolate (5-formylTIIF) for 18 hours (h) to label intracellular folate 
pools, which were subsequently quantitated by high performance liquid 
chromatography (HPLC). In AML 5-methylTIIF made up 53% of the total folate 
pool followed by 10-formylTIIF (26%), 5-formylTIIF (10%), TIIF (9%) and DHF 
(1%). Cells from ALL differed from AML (p<O,OS) with respect to 10-formylTIIF 
(17%) and DHF (10%). 
Exposure to nitrous oxide (8 h) caused an equal decrease of 10-formylTIIF and 
5-formylTIIF in both AML (30%) and ALL (45%), whereas 5-methylTIIF increased 
(130%). Methotrexate (4 h, 10-(;M) caused an accumulation of DHF and a decrease of 
5-methylTIIF in both AML (32%) and ALL (12%). A specific reduction of the 
10-formylTHF (50%) and 5-formylTHF (25%) pools was noticed in ALL. Exposure to 
nitrous oxide prior to methotrexate treatment aggravated the reduction of 
10-formylTIIF and 5-formylTIIF presumably by impaired replenishment from the 
5-methylTHF pool. In conclusion, this study demonstrates a significant difference in 
folate coenzyme distribution between cells from AML and ALL. Moreover it is shown 
that nitrous oxide and methotrexate treatment of leukemic cells cause an 
accumulation of 5-methylTHF and DHF respectively at the expense of other folate 
forms. The presence of substantial amounts of DHF in cells from ALL together with 
the specific reduction of 10-formylTHF (necessary for purine synthesis) during MTX 
treatment may in part explain the efficacy of methotrexate in the treatment of ALL. 
5.2. Introduction. 
Folate coenzymes play an important role in the biosynthesis of purines and 
thymidylate (dTMP) (1), precursors of RNA and DNA This immediate importance to 
cellular proliferation makes the metabolism of reduced folates a potential target in 
the chemotherapeutic treatment of malignancies. Structural analogues of folate, 
especially methotrexate (MTX), have demonstrated the success of this approach (2). 
Most research on the folate metabolism and interfering drugs has been performed in 
experimental animals and cell lines, as studies on fresh human material (ex vivo) have 
been hampered by the instability of the various folate coenzymes and even more by 
their low intracellular concentration (3,4,5,6). Recently, Baram et al. (7) demonstrated 
the stable radioactive labeling of these coenzymes pools in fresh human myeloid 
precursor cells, allowing extensive investigations on the folate metabolism with a 
minor amount of biological material. 
In the following study this particular method has been used to determine the folate 
coenzyme distribution in blast cells from patients with acute leukemia. In order to 
further elucidate the significance of the various folate cofactor pools, we studied the 
response of leukemic cells to 2 drugs interfering with the folate metabolism: nitrous 
oxide and methotrexate (MTX). 
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Nitrous oxide inactivates the cobalamin coenzyme of methionine synthase 
(methyltetrahydrofolate homocysteine methyltransferase, E.C.2.1.1.13) (8). This 
enzyme plays an essential role in the cellular retention of reduced folates by 
demethylating new intracellular 5- methylTHF to THF, thereby facilitating 
polyglutamation and conversion to other less exchangeable folate forms. Cobalamin 
inactivation by nitrous oxide therefore leads to accumulation of 5-methylTHF at the 
expense of other reduced folates which forms the quintessence of the "methylfolate 
trap" hypothesis of cobalamin deficiency (1,9). The final results of this disturbance in 
the folate metabolism are the impaired de novo synthesis of dTMP and purines as a 
consequence of depleted folate coenzyme pools. 
Methotrexate (MTX) is a strong inhibitor of dihydrofolate reductase (DHFR) (2). 
The induced accumulation of DHF also causes disturbed de novo purine and dTMP 
synthesis by depletion of the required folate coenzymes. Moreover intracellular 
formation of DHF and MTX polyglutamates during MTX treatment causes direct 
inhibition of both AICAR transformylase, an important enzyme of purine synthesis 
and dTMP synthase (7,10,11). 
In man, both normal and malignant hemopoiesis have proven to be vulnerable to 
the effects of nitrous oxide (8,12,13,14) and MTX (2) on folate metabolism. In the 
following study, the specific redistribution of folate coenzymes in fresh leukemic cells 
during exposure to both drugs is investigated. 
5.3. Materials and methods. 
Chemicals. Methotrexate and 5-formylTHF were obtained from Lederle (Etten-Leur, 
The Netherlands). The premixed gas cylinder containing 50% nitrous oxide, 20% 
oxygen, 25% nitrogen and 5% carbon dioxide was purchased from Hoekloos 
(Schiedam, The Netherlands). fH] (6S) 5-formylTHF (Specific activity: 40 Ci/mmol) 
was obtained from Moravek Biochemicals (Brea, CA, U.S.A). Bovine Serum Albumin 
(B.S.A) was obtained from Sigma (St. Louis, MO, U.S.A), Lymphoprep from 
Mycomed (Oslo, Norway) and Fetal Calf Serum (F.C.S.) from Flow (Rickmansnorth, 
England). Hog kidney hydrolase was prepared according to Me Martin et al. (15), 
pure human transcobalamin II was purified from Cohn's fraction III according to Van 
Kapel et al. (16). RPMl 1640 medium and Hanks Balanced Salt Solution (HBSS) 
were prepared in the laboratory. 
Patient material. Bone marrow aspirates and peripheral blood samples were obtained 
after informed consent from healthy volunteers and leukemia patients at presentation. 
Acute myeloid leukemias were classified according to the F AB classification on both 
morphological and cytochemical criteria (17). Cases of acute lymphoid leukemia were 
classified according to immunological phenotype. The percentage blast cells in each 
sample was determined in a differential count of 500 cells. 
Radioactive labeling of intracellular folate pools. Bone marrow aspirates and peripheral 
blood were collected in EDTA containing tubes. The mononuclear cells were isolated 
by lymphoprep centrifugation and washed with HBSS, 0,2% BSA Monocytes and 
macrophages were removed by adherence to a large (150 cm2) culture flask during a 
one hour incubation of the cells in HBSS with 10% FCS at 37 oc. The percentage 
blasts in the final leukemic cell suspensions always exceeded 80%. Cells were labelled 
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with eHJ 5-formylTHF according to Baram et al. (7). A suspension of 2.106 cells per 
ml in RPMI 1640 (without folic acid or cobalamin), containing 10% dialysed F.C.S., 
50 nM fH] 5- formylTHF and 40 pM transcobalamin ll was prepared. Mter 
incubation at 37 °C, 5% C02 for 18 hours, cells were washed with HBSS, 0,2% BSA 
and resuspended (at 2.106 cells/ml) in RPMI 1640 without folic acid or cobalamin, 
containing 10% dialysed F.C.S. 
Exposure of leukemic cells to nitrous oxide and/or MTX. Mter resuspension, 6.106 cells 
were used for direct determination of total intracellular fH] folate content and HPLC 
separation of the folate coenzymes (see below). If available, remaining leukemic cells 
were divided over 4 culture flasks (6.106 cells in 5 ml RPMI 1640 per flask). Two 
flasks were exposed to nitrous oxide by flushing during 15 minutes with a filtered 
mixture released from a premixed cylinder. Subsequently, the culture flasks were 
closed and incubated at 37 oc for 8 hrs. The 2 other flasks were flushed with a 
mixture of air and 5% carbon dioxide for 15 minutes and also incubated for 8 hours 
at 37 °C. MTX in a negligible volume was added for just the last 4 hrs of incubation 
(concentration: lO"'M) to one flask flushed with nitrous oxide and one with air. Before 
and after incubation, cell viability (trypan blue exclusion) and cell concentrations were 
checked. Total cell loss never exceeded 10 %. 
Quantitation of folate coenzyme pools. Mter incubation, cells were washed with HBSS, 
0,2% BSA and counted, a sample was drawn from each flask for measurement of 
total intracellular rHJ folate content. A standard mixture of unlabeled folates was 
added to the remaining cells. Subsequently, folates were extracted according to Baram 
et al.(7), using a 90 s boil of the cell pellet in 2 ml 2% mercaptoethanol, 2% ascorbic 
acid, pH 6.0. Mter treatment for 1 h with hog kidney hydrolase in order to break 
down folate polyglutamates, again 2 ml of the extraction solution was added prior to 
an additional 90 s boil. Folates were further purified and concentrated on C18 
SEP-PAK cartridges, and than separated by reverse phase HPLC essentialy as 
described by Allegra et al. (10), with the following modifications. The prepared folate 
extracts were dissolved in 400 ul 2% mercaptoethanol/2% vitamin C pH 6.0. From 
this extract 200 ul was injected onto a chromsphere C18 column, 200 x 3 mm 
(Chrompack Inc., Bridgewater, NJ, USA). Elution conditions: 0-15 minutes: isocratic 
with 10 mM ammoniumphosphate, SmM Pic A, 12,5% methanol, pH 5.5. 15-49 
minutes: linear gradient from 12,5% to 22% methanol in same buffer. The flow was 
0.4 ml/minute. Retention times of folates were as follows: 10-formylTHF: 21.2 min., 
THF: 24.2 min., 5-formylTHF: 28.9 min., DHF: 31.9 min., 5-methylTHF: 37.9 min. 
Samples were collected at 30 s intervals. The amount of radioactive folates was 
quantitated by liquid scintillation counting. Unlabeled folate standards were detected 
at 290 nm with a spectrophotometer (Spectroflow 757, Kratos) and used for 
identification of the radioactive folate peaks. Background counts in the HPLC eluate 
were ± 100 dpm, fractions of folate peaks contained 100-2000 dpm above the 
background. Before and after analysis of radioactive extracts, unlabeled standard 
folate mixtures (the same as mentioned above) were injected onto the HPLC system. 
Calculation of intracellular radioactive folate pools was based on the recovery of the 
unlabeled folate standards in the cell extract, and the amount of radioactivity in the 
peaks. Although present in small amounts, 5,10-methyleneTHF could not be 
quantitated accurately in the present study. 
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Statistical evaluation. Observed differences between folate cofactor pools of AML and 
ALL were statistically tested with the Mann-Whitney U Test. Treatment effects of 
MTX and/ or nitrous oxide were tested against the control values with the Wilcoxon 
signed rank test for paired observations. 
5.4.Results.. 
Intracellular folate coenzyme distribution. Folate coenzyme levels were analysed in 
normal bone marrow (n=5) and leukemic cells after 18 hours of incubation with 5.10-a 
M ['H] 5-formylTHF. Samples of 10 cases of AML and 5 cases of ALL were 
investigated (table 5.1). Total intracellular LHJ folate was highest in cells from AML 
followed by ALL and normal bone marrow cells. Overall, there was a large variety in 
the specific folate coenzyme levels among the studied leukemia samples. 
5-MethylTHF was the major cofactor in all cells, representing 52%, 55% and 60% of 
the total ['H] folate in respectively AML, ALL and normal bone marrow (table 5.1). 
A significant difference (p < 0,05) between AML and ALL was noticed in the 
intracellular levels of 10-formylTHF (resp. 26% and 17%) and DHF (resp. 1% and 
10%). Interestingly, the fraction of intracellular ['H] folate present as 5- methylTHF 
was increased while 10-formylTHF was decreased in the cells from cases of more 
differentiated AML and ALL (patient 8,9,10 and 15). The folate distribution of 
normal bone marrow cells was almost identical to the pattern observed in myeloid 
leukemias. 
Effed of drug treatment on total tHJ folate content. From the samples of AML 
patients 1,3,4,5,7 and of all patients with ALL enough cells could be isolated to 
perform experiments with nitrous oxide and/ or MTX. After incubation for 8 hrs in 
folate free RPMI 1640, untreated AML and ALL cells had lost 17% and 25% of their 
initial [3H] folate content (table 5.2). However, no change in the folate coenzyme 
distibution was noticed. Exposure of the cells to nitrous oxide (8 hrs) and/or MTX 
(10_. M, the last 4 hrs) did not affect the total ['H] folate content of the AML cells 
but 12 % loss occurred in ALL cells only during combined nitrous oxide/MTX 
treatment. 
Effects of nitrous oxide on folate pools. Exposure of the leukemic cells to nitrous oxide 
for 8 hrs caused an increase of 5-methylTHF to 130% and an equivalent decrease of 
10- formylTHF and 5-formylTHF of 30% in AML and 45% in ALL (figure 5.1). 
Moreover, a 35% decrease of THF was noticed in AML cells and a 45% reduction of 
DHF in ALL cells. 
Effect of MTX on folate pools. Incubation of the leukemic cells with 10_. M MTX for 4 
hrs largely increased the DHF pools in both AML and ALL cells (figure 5.1). In 
AML cells this rise of DHF was accompanied by a 33% decrease of 5-methylTHF. 
ALL cells predominantly compensated the accumulation of DHF by a decrease of 
10-formylTHF (50%) and 5-formylTHF (25%) and just a small reduction of the 
5-methylTHF level. For 10-formylTHF this difference between AML and ALL cells 
was statistically significant (p<0,01). Studies of Baram et al. (18) have shown that 
during MTX treatment of cells, substantial amounts of 10-formylDHF are produced. 
With the HPLC separation of folates employed for this study, THF and 
10-formyiDHF co- elute and cannot be distinguished from each other. The indicated 
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Table 5.1: 
Intracellular rH] folate coenzyme levels (fmol per 106 cells) in bone marrow from 
healthy persons and leukemia patients. 
No. Diagnose Source Total N1°Formyl N5Formyl DHF THF MTHF 
M1 B.M. 531 186 53 0 42 260 
2 M1 P.B. 641 288 103 0 90 160 
3 M2 B.M. 652 174 67 17 67 328 
4 M4 P.B. 554 131 27 0 60 326 
5 M4 B.M. 453 122 41 0 23 267 
6 M4 P.B. 277 75 22 11 19 147 
7 M4 B.M. 448 99 31 13 31 278 
8 M5B B.M. 745 66 37 0 67 574 
9 M5B B.M. 485 53 49 0 44 340 
10 M5B B.M. 517 88 16 0 0 414 
Mean ± s.e.m.: 530 ±40 128 ± 21 45±8 4±2 44±8 299 ±42 
% of total uptake: 100% 26% 10% 1% 9% 53% 
11 cALL B.M. 326 66 29 49 49 137 
12 cALL P.B. 653 39 7 20 7 574 
13 cALL B.M. 465 107 32 60 32 233 
14 cALL B.M. 425 123 77 85 77 72 
15 TALL P.B. 171 12 0 0 0 137 
Mean ± s.e.m. 408±72 69± 19 29 ± 12 43 ± 13 36±8 230 ± 81 
% of total uptake: 100% 17% 7% 10% 10% 55% 
Normal bone marrow: 313 ±55 74±9 22±3 7±3 22±5 188 ± 40 
(mean± s.e.m., n = 5) 
% of total uptake: 100% 24% 7% 2% 7% 60% 
Intracellular folate pools of bone marrow cells were labeled by 18 hrs incubation with 50 nM fH] 
5-formyiTHF prior to quantitation of the folate cofactor pools by HPLC analysis. B.M.: bone marrow, 
P.B.: peripheral blood. 
Figure 5.1 (opposite page): Effect of nitrous oxide and/or MTX on intracellular [H3) folate levels in cells 
from AML (n=5, top panel) and ALL (n=5, bottom panel). Intracellular folate pools of blast cells from 
leukemia patients were labeled by 18 hrs incubation with 50 nM rHJ 5-formylTHF. Subsequently cells 
were exposed to air (8 hrs), nitrous oxide (8 hrs), air (8 hrs) and MTX (10-6 M, last 4 hrs) or nitrous 
oxide (8 hrs) and MTX (10-6M, last 4 hrs), prior to quantitation of the folate cofactor pools by HPLC 
analysis. See Material and Methods section for specific incubation conditions. N10: 10-formylTHF, ~: 
5-formylTHF, DHF: dihydrofolate, THF: tetrahydrofolate, FDHF: 10-formyldihydrofolate, MTHF: 
5-methylTHF. (*:statistically different from controls, p<O,OS) 
Erratum:"top panel" and "bottom panel" are "left panel" and "right panel". 
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Table 5.2: 
Total intracellular [3H] folate content (fmol per 106 cells) of blast cells 
derived from AMl and All patients. 
Diagnose n Preincubation Control N20 MTX N20+MTX 
AML 5 498 ± 65 412 ± 30 400 ± 30 411 ± 39 400 ± 31 
ALL 5 408 ± 72 300 ± 41 276 ± 29 285 ± 42 249 ± 36 
Intracellular folate pools were labeled by 18 hrs incubation with 50 nM [3H] 5-formyiTHF 
prior to exposure to air (8 hrs), nitrous oxide (8 hrs), air (8 hrs) and MTX (1 o-s M, last 4 hrs) 
or nitrous oxide (8 hrs) and MTX (1 o-s M, last 4 hrs). Subsequently samples were drawn 
form the cell suspensions for determination of total [3H] folate content 
increase of THF during MTX treatment is therefore most likely caused by the 
presence of 10-formylDHF. 
Effect of nitrous oxide and MTX on folate pools. The exposure to nitrous oxide for 8 
hrs combined with the 10-<~ M MTX incubation during the last 4 hrs resulted in a 
substantial increase of DHF at the expense of 10-formylTHF and 5-formylTHF in 
both types of acute leukemia cells (figure 5.1). However the response of cells from 
ALL to the nitrous oxide/MTX treatment was more profound, causing a 70% 
depletion of both formylated reduced folates versus 25% in AML cells. This 
difference between AML and ALL was significant (p<0,01). Both 5- methylTHF and 
the THF /10-formylDHF pools remained unchanged. 
5.5. Discussion. 
Studies on nitrous oxide exposure or MTX treatment on the intracellular folate 
metabolism have predominantly been carried out in respectively animals (1,3) and cell 
lines (10,11,18-20). The present paper, for the first time, provides information on the 
folate coenzyme levels of fresh human leukemic cells and the effects of nitrous oxide 
and/ or MTX and compared with untreated normal bone marrow cells. The results of 
the latter are in accordance with literature data on myeloid precursor cells (7), which 
favors the reliability of the employed methods. 
Although there is a wide variation in the concentrations of the various folate forms 
in leukemic cells after incubation with rH] 5- formylTHF, several conclusions can be 
drawn. In both AML and ALL cells, 5-methylTHF was the predominant folate form 
accounting for more than 50% of the total folate pool. In purified myeloid precursor 
cells from normal bone marrow 5-methylTHF and 10-formylTHF appeared to be 
present in about equal concentrations (7). In contrast with this, we found that 10-
formylTHF accounted for only 26% of the total rHJ folate pool in AML cells and 
17% in ALL cells. This difference between AML and ALL is difficult to explain as 
additional data on proliferation index and rate of purine synthesis are not available. 
Cells from several subtypes of AML have been used. The data in table 5.1 suggest 
that a higher differentiation level of myeloid leukemic cells is accompanied by an 
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increase in 5-methylTHF (from 38% to 70% of total rHJ folate) and a decrease of 
10-formylTHF (from 40% to 9% of total rHJ folate). This observation concurs with 
the general assumption that high levels of 5-methylTHF are indicative for 
well-differentiated tissues (3,4,5,6). Probably this also explains why the fraction of 
5-methylTHF in purified myeloid precursors (7), appeared to be smaller than in the 
normal bone marrow samples in this study which still contain differentiated cells. 
DHF was scarcely present in AML blast cells nor in normal bone marrow cells. 
However substantial levels of DHF were noticed in ALL cells, which is in contrast 
with folate distributions reported in animal tissues (3,4,5,6) and cell lines (19,20). 
Kamen et al. (21) showed the activity of dihydrofolate reductase (DHFR) in ex vivo 
ALL cells to be very low compared to cell lines and animal tissues. As the enzyme is 
very stable (21) these data suggest that the presence of DHF in ALL cells may result 
from a restricted activity of dihydrofolate reductase. 
Eight hours after incubation with rHJ 5-formylTHF, some loss of fH] folate from 
the leukemic cells has occurred however without change of the folate coenzyme 
distribution. This demonstrates the stability of the equilibrium, achieved by the 18 hrs 
incubation with rHJ 5-formylTHF. The rH] folate content was higher in AML than in 
ALL cells which agrees with earlier investigations which showed a higher total folate 
content of cells from AML compared with ALL (22,23). 
Based on previous studies by Boss (24) and Baram et al. (7), 8 hrs of nitrous oxide 
exposure and/or 4 hrs incubation with lif M MTX were used to interfere effectively 
with the folate metabolism of the leukemic cells. In our study the inactivation of 
methionine synthase by nitrous oxide did not reduce the total intracellular fH] folate 
content (3), which may require a longer nitrous oxide exposure, but it did induce a 
significant redistribution of the folate coenzymes. In both AML and ALL cells the 
5-methylTHF pool rose at the expense of the other folate coenzymes, which supports 
the "methyl trap hypothesis" for cobalamin deficiency (3,9). The substantial depletion 
of 10-formylTHF during nitrous oxide exposure may imply an important reduction of 
purine synthesis during cobalamin inactivation, as has been suggested before (24). 
The effects of MTX on folate coenzyme pools differs significantly between blast 
cells from AML and ALL. In both types of acute leukemia, the inhibition of DHFR 
resulted in a steep rise of the DHF pool and probably also of the 10-formylDHF 
pool. In AML cells this accumulation of oxidized folates went mainly at the expense 
of 5-methylTHF, as has been decribed before for purified myeloid blasts from normal 
bone marrow (7). However, MTX treatment of ALL cells caused substantial depletion 
of 5-formylTHF and more importantly of 10-formylTHF. This reduction of 10-
formylTHF may have a negative effect on the activity of AICAR and GAR 
transformylase and suggests an relatively high sensitivity of the purine metabolism in 
ALL cells for MTX. 
Prior inactivation of methionine synthase by nitrous oxide exposure aggrevates the 
effect of MTX because the partial replenishment of the other decreased folate 
coenzymes levels by conversion of 5-methylTHF to THF has been made impossible. 
Especially in ALL cells this results in severe depletion of both 10-formylTHF and 
5-formylTHF, The increased toxicity of MTX on bone marrow after nitrous oxide 
anesthesia, (25, 26) may at least partially be ascribed to this mechanism. 
In conclusion, the dissimilarities in folate coenzyme pools between ALL and AML 
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cells suggest an intrinsic difference in the quantitative importance of several 
folate-dependent pathways. Especially the presence of DHF in ALL cells, suggesting 
low DHFR activity, may be clinically relevant. Moreover, the more pronounced 
depletion of 10-formylTHF in ALL cells during inhibition of the normal folate 
metabolism is also in support of a higher MTX sensitivity of ALL cells than AML 
cells, which may be reflected by the fact that MTX has been retained in many ALL 
but not in AML treatment protocols. 
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6.1. Summary. 
Nitrous oxide inactivates the cobalamin coenzyme of methionine synthase. This 
enzyme plays an essential role in the cellular retention of reduced folates. Earlier 
studies have shown that prolonged exposure (>24 h) to nitrous oxide can result in 
macrocytic/megaloblastic bone marrow depression as a consequence of impaired 
folate-dependent synthesis of thymidylate ( dTMP). In the present study the effect of 
shorter periods of continuous exposure to nitrous oxide (7-12 h) on hematopoiesis was 
investigated, using in vitro assays to determine the number of myeloid and erythroid 
progenitors, present in the bone marrow. Bone marrow samples from 14 patients (pts) 
before and after nitrous oxide anesthesia were obtained. Four pts, operated on under 
total intravenous anesthesia, served as controls. Macrocytic changes of the bone 
marrow were noticed in only two pts exposed to more than 24 h nitrous oxide over a 
3 day period. Disturbance of the deoxyuridine suppression test value of the bone 
marrow cells at the end of anesthesia occurred in all pts undergoing nitrous oxide 
exposure. Both myeloid and erythroid progenitors, cultured in vitro, increased in 6 pts 
(160%) and decreased in 6 other pts (40%). Increase occurred in pts with a normal 
bolo- transcobalamin II and folate level. Decrease of the hematopoietic progenitors 
was related to nitrous oxide exposure for more than 24 h (2 pts) or low plasma 
holo-transcobalamin II and/or low plasma folic acid (4 pts). Still, the number of 
progenitors present in the bone marrow after nitrous oxide anesthesia never 
decreased below the lower limit of normal values. It can be concluded that although 
nitrous oxide induces changes in the proliferation kinetics of the hematopoietic 
compartment within the studied exposure periods, the toxic effect on bone marrow 
functioning is limited. 
6.2. Introduction. 
Early clinical observations in tetanus patients have shown that prolonged exposure to 
nitrous oxide could result in megaloblastic bone marrow depression (1). Later 
investigators correlated this clinical effect of nitrous oxide exposure to the chemical 
reactions which can occur between cobalt(!) complexes, like cobalamin, and nitrous 
oxide (2,3). Since then further research, both in man and test animal, has been aimed 
at elucidation of the effects of prolonged exposure to nitrous oxide on cobalamin 
dependent metabolism (for review see: 4,5). It was found that nitrous oxide 
specifically inactivates the methylcobalarnin coenzyme of methionine synthase. This 
enzyme plays a crucial role in the cellular retention of reduced folates by conversion 
of homocysteine and methyltetrahydrofolate, the major extracellular folate, to 
methionine and tetrahydrofolate which subsequently can be polyglutamated and 
converted to other active folate coenzyme forms. Prolonged exposure to nitrous oxide 
therefore causes cellular folate depletion and disturbance of folate-dependent 
methylation reactions such as the de novo synthesis of thymidylate ( dTMP) and 
purines. Obviously the rapidly dividing cells of the hematopoietic compartment are 
very dependent on the intact function of the methylcobalamin coenzyme. 
Several studies have revealed a relation between the duration of exposure to 
nitrous oxide, inactivating human methionine synthase with a half time of ±46 
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minutes (6), and the changes that occur in the bone marrow. The deoxyuridine 
suppressiontest (dU test) value is a reliable assay for measuring disturbance of the 
folate-dependent dTMP synthesis. In fit patients, increase of the dU test requires S-6 
h of nitrous oxide exposure (7). Megaloblastic changes of the bone marrow only occur 
after 12-24 h of nitrous oxide exposure (2,8,9). Data on the events which occur 
between the first sign of biochemical changes in the bone marrow and the onset of 
morphological changes are not available. 
In this study, we determined the number of myeloid and erythroid progenitors cells, 
present in the bone marrow of patients exposed to nitrous oxide. During in vitro 
culturing of bone marrow cells in semi- solid culture medium, proliferation of these 
myeloid and erythroid progenitors produces recognizable groups of descending cells 
(called "colonies" and ''bursts" respectively) which enables their quantitation in marrow 
aspirates. Both progenitors (called Colony Forming Unit- Granulocyte/Macrophage 
(CFU-GM) and Burst Forming Unit-Erythroid (BFU-E) respectively) represent less 
than 1% of the bone marrow cells and are involved in self renewal and proliferation 
of the hematopoietic compartment. This immediate importance to hematopoiesis, 
together with their ability to produce colonies during in vitro culture, has resulted in 
the application of clonogenic assays for the estimation of bone marrow functioning. 
In the present study, correlations between these data, bone marrow morphology, 
dU test values and the cobalamin/folic acid status were established. 
6.3. Materials and methods. 
Patients.. Eighteen patients undergoing prolonged anesthesia for plastic surgery (10 
pts), tumor resection (6 pts) or trauma treatment (2 pts) were studied. None of them 
were critically ill. Nitrous oxide was used in 14 cases, total intravenous anesthesia 
without nitrous oxide in the other 4 patients. Patients'informed consent was obtained. 
All subjects were hematologically normal as assessed by preoperative values for 
hemoglobin, hematocrit, mean corpuscular volume and leucocyte count. Patients 
previously treated with cytostatics or radiation were excluded. 
Anesthesia. 
-Nitrous oxide exposed group (14 pts): induction: thiopentone (3-6 mgjkg), 
maintenance: nitrous oxide (70% ), oxygen (30 % ), enflurane (0,5-1%) and fentanyl, 
relaxation: pancuronium (0,1 mg/kg). 
-Control group (4 pts): induction: propofol (2-3 mg/kg), maintenance: oxygen 
enriched air, propofol (10-6 mg/kg/h) and fentanyl, relaxation: pancuronium (0,1 
mg/kg). 
Except for nitrous oxide, none of the applicated drugs is known to interfere with the 
activity of methionine synthase. Physiological parameters were always kept within 
normal limits. Transfusions of erythrocyte concentrates were given to all patients 
when necessary. 
Procedures. Venous blood (10 ml) was collected preoperatively in an EDTA 
containing tube for determination of plasma cobalamin, holo-transcobalamin II and 
folate. Bone· marrow was sampled from the anterior iliac crests immediatly after 
induction and at the end of anesthesia. It was collected in EDTA containing tubes. 
This material was used for bone marrow smears, the dU test, and clonogenic assays. 
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Plasma folic acid and cobalamin were determined simultaneously with a radioassay 
(Becton-Dickinson, Orangeburg, New York, USA). Plasma bolo- transcobalamin II 
was determined according to Van Kapel et al. (10). Bone marrow smears were made 
directly after aspiration and stained with May Grunwald-Giemsa. 
DU suppression/est Cells were isolated from the bone marrow sample by Ficoll-Paque 
centrifugation. A portion of the obtained cells was subjected to the dU test as 
described by Metz et al. (11). Briefly, cells preincubated with 0,1 mM deoxyuridine 
for 1 h are incubated with [IP] thymidine for an extra hour. If the folate dependent 
dTMP synthesis is normal, the preexposure to deoxyuridine will suppress [IP] 
thymidine incorporation to less than 10% of the control incubations without 
deoxyuridine. However, in case of disturbed folate metabolism, this ratio increases 
rapidly. 
Clonogenic assays. Bone marrow cells (lOS) were plated in triplicate in 1 m1 Alpha 
medium containing 0,9% methylcellulose, 20% fetal calf serum, 1% bovine serum 
albumin, 3.10.s M lecithin, 3.10"" M transferin and 2.10-s M mercaptoethanol. Myeloid 
growth was supported by addition of 10% Giant Cell Tumor-Conditioned Medium. 
Erythroid growth was supported by 10% Phytohaemagglutine Leukocyte-Conditioned 
Medium and 2 units r-erythropoietin per ml. Colony Forming Unit-Granu-
locyte/Macrophage (CFU-GM) and Burst Forming Unit-Erythroid (BFU-E) were 
counted respectively on day 10 and day 14 of incubation at 37 C, 5% CO,. 
Data analysis. Non-parametric statistical analysis of the obtained data was performed 
on the ratio's of post-and preoperative values of the deoxyuridine suppression test, 
and the ratio's of post-and preoperative numbers of CFU-GM and BFU-E present in 
lOS bone marrow cells. Differences between patients operated on under nitrous oxide 
anesthesia and patients operated on under TIV A were tested with the Mann-Whitney 
U test. The same test was used to evaluate the difference between normal patients 
and patients with a low plasma cobalamin and/ or low folate. Correlation between 
nitrous oxide exposure time and the post and preoperative ratio's was calculated with 
the Spearman rank correlation test. All p values are given as one-tailed. 
6.4. Results. 
Preoperative blood parameters. The preoperative hematological values of all patients 
(see M&M) were within the normal range. Table 6.1 reveals that this study included 7 
patients with a low plasma folate ( < 7 nM) of which 5 were operated on under nitrous 
oxide and 2 under TIV A Two patients had a low serum cobalamin ( < 120 pM) and 3 
low holotranscobalamin II ( <20 pM). All others had normal plasma levels and will be 
referred to as "normal patients". One patient had a low serum cobalamin but a 
normal bolo- transcobalamin II and was therefore also considered "normal". 
Effect of anesthesi!J on marrow morplwlogy and dU test values. Preoperative dU tests 
and bone marrow morphology were normal in all patients. Continuous anesthesia 
varied from 390 to 720 minutes. After anesthesia, macrocytic changes were noticed 
only in bone marrow aspirates from 2 patients who had undergone multiple nitrous 
oxide exposures. The dU test increased to abnormal values ( > 10%) in all patients 
who underwent nitrous oxide anesthesia (p<O.OOl, table 6.1) but no correlation was 
seen between the exposure time and the observed increases. However, the 
Table 6.1: 
Age (in years), sex, duration of anesthesia (in minutes), preoperative plasma parameters and 
preoperative (T1) and postoperative (T J bone marrow parameters of patients involved in 
this study. 
PATIENTS OPERATED ON UNDER NITROUS OXIDE ANESTHESIA 
WITH NORMAL PLASMA COBALAMIN AND/OR FOLATE LEVELS. 
Age Sex Anesthesia Cobalamin TCII Folate DUtest CFU-GM BFU-E 
duration (pM) (pM) (nM) T, Tz T, Tz T, Tz 
56 M 390 225 30 7.9 10 15 66 78 72 83 
74 F 480 204 53 10.0 5 27 75 115 20 35 
20 M 530 182 23 37.3 10 53 62 82 66 77 
49 F 600 322 86 7.7 11 29 ND ND ND ND 
39 M 615 88 21 8.3 3 32 87 163 80 148 
40 M 630 309 51 8.4 8 21 ND ND ND ND 
65 F 720 272 67 12.0 ND ND 35 82 48 88 
53 M 1440* 330 65 18.1 11 22 250 107 258 100 
18 M 1680* 287 49 16.3 10 24 45 30 108 83 
PATIENTS OPERATED ON UNDER NITROUS OXIDE ANESTHESIA 
WITH LOW PLASMA COBALAMIN AND/OR FOLATE LEVELS. 
Age Sex Anesthesia Cobalamin TCII Folate DUtest CFU-GM BFU-E 
duration (pM) (pM) (nM) T, Tz T, Tz T, Tz 
65 M 400 165 32 6.4 6 37 37 26 ND ND 
18 M 420 167 34 4.4 8 54 278 168 197 142 
27 F 425 109 8 4.8 9 34 44 25 27 17 
54 M 460 185 43 4.7 10 39 75 90 42 42 
65 M 580 70 17 6.8 9 61 169 63 64 33 
PATIENTS OPERATED ON UNDER TOTAL INTRAVENOUS ANESTHESIA. 
Age Sex Anesthesia Cobalamin TCII Folate DU test CFU-GM BFU-E 
duration (pM) (pM) (nM) T, Tz T, Tz T, Tz 
70 M 520 186 16 4.4 8 7 57 54 40 46 
17 M 540 138 14 15.7 9 9 180 188 91 86 
51 M 560 184 23 14.2 5 4 221 216 128 134 
18 M 600 296 51 6.5 10 9 90 93 93 89 
Deoxyuridine suppression test (DU test) values are expressed as the ratio x 1 00 % between [3H] thymidine incorporation in 
bone marrow cells with and without deoxyuridine preincubation (see Materials and Methods). Myeloid (CFU-GM) and 
erythroid (BFU-E) progenitors present in bone marrow are given as the number per 105 marrow cells.*: Total exposure to 
nitrous oxide over 3 days. (Normal range cobalamin: 120-800 pM, transcobalamin II: 20-220 pM, folate: 7-30 nM) 
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postoperative dU test values from patients with a low folate and/ or cobalamin level 
differed significantly from normal patients (p < 0.05). 
Ejfed of anesthesia on CFU-GM and BFU-E (Table 6.1). In patients with total 
intravenous anesthesia no changes in the number of assayable hematopoietic 
progenitors occurred. However in nitrous oxide treated subjects two patterns seemed 
to evolve. In patients with normal folate/cobalamin levels, nitrous oxide exposure 
caused accumulation of both CFU-GM and BFU-E. The correlation between the 
80 
increase of CFU-GM in bone marrow of normal subjects was statistically significant 
(n=5, r.=0.90, p<O.Ol). On the other hand, in patients with low plasma cobalamin 
and/or folate the exposure to nitrous oxide decreased the number of both progenitors 
present in bone marrow. The difference between normal patients and patients with a 
low plasma cobalamin and for folate was significant (p<0.05). The 2 patients who 
received several nitrous oxide exposures over a short period also showed a decrease 
in CFU-GM and BFU-E. However, in none of the patients the number of both types 
of progenitors present in bone marrow decreased below the lower limit for normal 
values (in our laboratory: 25 colonies per lOS cells). 
6.5. Discussion. 
So far, nitrous oxide is the only drug known to inactivate the function of the 
cobalamin coenzym in methionine synthase. This eventually causes disturbance of the 
folate-dependent dTMP and purine synthesis and slowing down or arrest of cells 
shortly after starting DNA synthesis. The final result of this process is an 
asynchronous pattern between nuclear and cytoplasmic maturation, which is 
characteristic for megaloblastic bone marrow. 
Most investigations on hematological toxicity of nitrous oxide have focused on 
exposure periods of 12-24 h. However, in seriously ill patients already short term 
exposure to nitrous oxide may lead to macrocytic/megaloblastic changes in the bone 
marrow (12). The purpose of the present study was to investigate the effect of 7-12 h 
nitrous oxide exposure on hematopoiesis of patients who were not critically ill as this 
situation occurs rather frequently. The application of clonogenic assays for 
quantification of myeloid and erythroid progenitors (CFU-GM and BFU-E) permitted 
the early detection of changes in the proliferation capacity of the hematopoietic 
compartment. 
The presented data show that the folate-dependent dTMP synthesis, as measured 
by the dU test, is indeed disturbed after exposure to nitrous oxide. The observed 
increase in CFU-GM and BFU-E by nitrous oxide exposure in patients with normal 
preoperative plasma folate/cobalamin levels is difficult to explain. However, a similar 
phenomenom has been described in rats (13) and human bone marrow cells during in 
vitro pertubation of the folate metabolism (14). Possibly the nitrous oxide-induced 
arrest of proliferating cells in S phase (15) results in accumulation/synchronisation of 
hematopoietic progenitor cells. Nitrous oxide-exposed patients with a low preoperative 
plasma folate/cobalamin level had the highest postoperative dU test values and in 
contrast a decrease in CFU-GM and BFU-E. Low plasma cobalamin and low plasma 
folate are not synonymous to a cobalamin or folate deficiency (16). However, studies 
in patients with subnormal plasma cobalamin or folate values have revealed elevated 
plasma homocysteine concentrations which suggests reduced methionine synthase 
activity in this particular group of subjects (17,18). Previous studies have also 
demonstrated that patients with deranged cobalamin and for folate metabolism are 
more susceptible to the toxic effects of nitrous oxide (9,19,20). An accelerated onset 
of toxicity on hematopoietic progenitors, therefore seems obvious. The decrease in 
progenitors, found in the two patients who underwent multiple nitrous oxide 
exposures, is probably caused by surpassing the critical period during which these cells 
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can survive the nitrous oxide-induced disturbance of folate metabolism. 
Still the postoperative values of CFU-GM and BFU-E present in the bone marrow 
after nitrous oxide exposure are within the normal range of our laboratory which 
indicates the sufficient functioning of hematopoiesis. Therefore the presented data 
suggest that although changes in the proliferation kinetics occur, the effect of 
continuous nitrous oxide exposure (up to 12 h) on bone marrow functioning in 
non-critically ill patients is rather limited. However, the observed accumulation of 
progenitors by nitrous oxide may contribute to an increased sensitivity of the 
hematopoietic compartment to S phase-specific cytostatics after withdrawal of 
anesthesia (7,13). Especially in compromized patients (e.g. low plasma 
folate/cobalamin) this phenomenom could rapidly result in unexpected 
myelosuppresion, even after short exposures to nitrous oxide (21,22). 
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7.1. Summary 
Exposure to the anesthetic gas nitrous oxide impairs the actiVIty of methionine 
synthase by oxidation of its cobalamin coenzyme. This enzyme catalyses the 
conversion of homocysteine and methyltetrahydrofolate to methionine and 
tetrahydrofolate respectively. Earlier studies have shown that hematological and/ or 
neurological damage, resembling cobalamin deficiency, may occur after prolonged or 
repeated inhalation of nitrous oxide. In the present study, effects of nitrous oxide 
anesthesia on homocysteine and folate metabolism have been investigated. 
Plasma levels of cobalamin, folate, homocysteine and methionine were determined 
in 40 patients before and after operation under nitrous oxide anesthesia (range of 
exposure time: 70-720 minutes). Twelve patients anesthetized with total intravenous 
anesthesia served as controls (range of exposure time: 115-600 minutes). 
Post-operative plasma levels of folate and homocysteine were found to be increased 
(p<0,001) up to 220 and 310%, respectively in nitrous oxide exposed patients while 
plasma levels of methionine were decreased (p < 0.025). Response already occurred 
after 75 minutes of nitrous oxide exposure. The percentage increase of plasma folate 
and homocysteine correlated significantly with exposure time (p < 0,025 and p < 0,0001 
respectively). After withdrawal of nitrous oxide, plasma levels of folate and 
homocysteine usually continued to rise for several hours. 
Return of plasma homocysteine to the preoperative level took more than 1 week 
(p<0.01) in 8 patients after anesthesia with nitrous oxide (range of exposure 
time:215-370 minutes). 
Urinary excretion of folate and homocysteine increased during and after nitrous 
oxide exposure (p<0,01 and p<0.002 respectively), and correlated with exposure time 
(p<0,01 and p<0.005 respectively). 
It can be concluded from this study that nitrous oxide-induced cobalamin 
inactivation can be monitored by determining plasma homocysteine. Moreover the 
presented data suggest that effects of nitrous oxide anesthesia on homocysteine and 
folate metabolism develop more rapidly than presently assumed and that return to 
normal requires several days. 
7:2. Introduction 
The widely used anesthetic gas nitrous oxide is known to oxidize the coenzyme 
methylcobalamin, causing irreversible inactivation of methionine synthase (1,2). This 
enzyme is responsible for the methyltransfer from 5-methyltetrahydrofolate to 
homocysteine (figure 7.1). Exposure to nitrous oxide may therefore disturb the 
intracellular folate metabolism and reduce the folate-dependent thymidylate and 
purine synthesis, necessary for DNA replication. In addition, the reduction of 
methionine synthase activity may result in a decrease of plasma methionine 
concentrations (3). 
Hematopoiesis in man depends strongly on the function of the methylcobalamin 
coenzyme and inactivation by prolonged exposure to nitrous oxide can cause 
megaloblastic changes of the bone marrow (1,3) similar to cobalamin deficiency. 
Moreover, neurological impairment which is well known in cobalamin deficiency, may 
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synthesis , ~ .... '¥ "-ir / 5-methyl THF homocysteine S-adenosylhomocysteine 
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Figure 7.1: Outline of the methylcobalamin-dependent conversion of 5-methyltetrahydrofolate 
(5-methylTHF) and homocysteine to tetrahydrofolate (THF) and methionine. 
occur after prolonged, intermittent, exposure to nitrous oxide ( 4 ). In critically ill 
patients (5) and folate and/or cobalamin deficient subjects (6) these effects may be 
provoked by nitrous oxide within few hours. However, in the majority of surgical 
patients receiving nitrous oxide anesthesia, the oxidation of methylcobalamin is 
regarded to be unharmful (7). 
Studies on hematological toxicity of nitrous oxide have mainly focused on bone 
marrow morphology and quantitation of the folate-dependent thymidylate synthesis in 
hematopoietic cells by means of the deoxyuridine suppression test (1,3,8). 
Recently, elevated serum levels of homocysteine have been reported in cobalamin 
and/ or folate deficient subjects (9) and cancer patients treated with high-dose 
methotrexate (10). The concentration of homocysteine in extracellular media like 
plasma and urine may therefore reflect perturbations of cobalamin-dependent folate 
metabolism. 
In the present study, we determined plasma levels of homocysteine, methionine, 
folate and cobalamin and renal excretion of homocysteine and folate in patients 
subjected to nitrous oxide anesthesia. 
Our results reveal an increase in plasma and urinary homocysteine and folate 
concentrations by nitrous oxide exposure within several hours, indicating that 
cobalamin inactivation occurs rapidly. This study shows that, among the studied 
parameters, plasma and urinary homocysteine are the most responsive to nitrous 
oxide-induced cobalamin inactivation. 
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7 .3. Methods 
Patients. Fifty four patients requiring plastic, otolaryngological or neurological surgery 
who underwent anesthesia with nitrous oxide (n=42) or total intravenous anesthesia 
(TIV A, n= 12) were included in this study. Informed consent was always obtained. 
Their ages varied from 18-81 years (Table 7.1). The duration of nitrous oxide 
anesthesia varied from 70 to 720 minutes (mean: 318±26), and for patients 
anesthetized with TIV A from 115 to 600 minutes (mean: 332±49). 
Two traumatized patients admitted for reconstructive surgery undergoing several 
operations during a three day period, were exposed to nitrous oxide for totally 24 
hours and 28 hours, respectively. Sixteen patients received 1-8 erythrocyte concen-
trates (200 ml per unit) and two-of them also received 1-2 units fresh frozen plasma 
(200 ml per unit) to compensate for blood loss during surgery (table 7.1). 
Anesthesia. The group of patients exposed to nitrous oxide received anesthesia 
including nitrous oxide (70% ), oxygen (30 % ), enflurane (0,5-1%) and fentanyl. The 
control group received anesthesia including oxygen enriched air, propofol (10-6 
mg/kg/h) and fentanyl. 
Protocol Venous blood from all patients was collected at the start and end of 
anesthesia, and the following parameters were routinely determined in plasma: total 
cobalamin, holotranscobalamin n, folate, methionine and total homocysteine. 
Voided urine was collected for 24 hours after the start of anesthesia from 19 
patients exposed to nitrous oxide and 10 patients anesthetized with TIV A, for 
determination of folate and homocysteine content. 
Blood samples from 6 patients exposed to nitrous oxide (patient 6, 7, 14, 19, 25 and 
38 in table 7.1) and 4 patients anesthetized with TIV A (patient 49, 50, 51 and 54 in 
table 7.1), were also collected hourly during anesthesia and repeatedly afterwards 
during 24 hours, for the above mentioned determinations. In addition free 
homocysteine was determined. Of the same patients, fractionated urine samples 
collected during 24 hours for determination of urinary folate and homocysteine 
excretion. 
From 8 patients (patient 10, 15, 17, 18, 20, 21, 26 and 27 in table 7.1) having being 
anesthetized between 215-370 minutes with nitrous oxide anesthesia (mean: 290± 19) 
the long term effect of nitrous oxide was studied in blood samples collected 1, 2 and 
7 days after the day of surgery. Six patients (patient 46-51 of table 7.1) anesthetized 
for 195 to 520 minutes with TIVA (mean: 313±44) were used as controls. 
Sample collection and processing. Ten ml of venous blood was collected into cooled, 
EDTA containing tubes and immediatedly placed on ice. Plasma was prepared by 
centrifugation within 5 minutes. For determination of free, acid soluble homocysteine, 
a portion (500 ul) of the sample was immediatly deproteinized with perchloric acid as 
descrbed (11). The samples of deproteinized and whole plasma were stored at -20 C 
until analysis. 
Analytical methods. Total homocysteine in plasma was determined by a fully 
automated assay recently developed in our laboratory (12). Free, acid soluble 
homocysteine in plasma as well as urinary homocysteine were assayed by a 
radioenzymic method (11). Protein-bound homocysteine is total homocysteine minus 
free homocysteine. 
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Table 7.1: 
Patient characteristics and preoperative plasma values of studied parameters. 
A Age Anesthesia Cabal. TCII FA HCY MET 
Nr (yrs) Sex (minutes) Transf. (pM) (pM) (nM) (!J.M) (!J.M) 
1 41 M 70 157 50 10.7 14.2 25.5 
2 26 F 75 147 24 5.9 16.8 21.9 
3 70 M 80 309 90 5.6 13.8 27.3 
4 50 F 130 719 298 21.0 7.2 14.4 
5 49 F 135 196 34 10.6 19.0 20.9 
6 32 M 135 254 49 5.0 12.0 19.3 
7 21 F 175 283 113 8.6 6.8 15.0 
8 26 F 175 184 51 3.1 16.3 24.1 
9 36 M 185 167 29 6.0 13.5 19.1 
10 24 F 215 435 155 6.4 7.8 20.9 
11 50 M 220 199 58 3.3 23.8 22.5 
12 50 M 220 612 249 16.0 112 19.4 
13 32 M 225 226 46 7.8 4.6 19.7 
14 74 F 225 224 40 4.2 14.2 23.3 
15 63 M 230 273 44 5.7 8.8 14.3 
16 33 F 230 1 EC 179 27 5.2 14.7 18.5 
17 40 M 255 220 48 5.8 9.6 27.3 
18 45 F 280 212 43 6.3 9.8 39.5 
19 29 M 300 287 45 5.0 8.1 18.5 
20 59 M 300 180 50 10.6 12.1 24.5 
21 72 M 305 121 24 8.4 12.7 19.0 
22 26 F 310 143 89 2.9 14.2 26.0 
23 41 F 310 233 67 4.8 12.9 27.9 
24 52 F 315 172 36 14.5 9.3 35.7 
25 47 F 320 3EC 515 82 2.8 8.4 24.9 
26 45 M 360 382 71 3.8 9.2 27.7 
27 46 M 370 315 102 16.4 11.4 25.8 
28 56 M 390 1 EC 325 30 7.8 11.2 17.6 
29 65 F 400 165 32 6.4 10.8 17.9 
30 18 M 420 167 34 4.1 14.6 31.1 
31 27 F 425 109 8 4.8 10.6 62 
32 54 M 460 2EC 185 43 4.7 8.3 18.8 
33 74 F 480 1 EC 204 53 10.0 6.7 13.6 
34 52 M 520 3EC 163 56 19.7 9.0 12.7 
35 71 M 555 174 34 8.0 10.3 16.3 
36 65 M 580 4EC 70 17 6.8 7.2 7.2 
37 49 F 600 1 EC 322 86 7.7 15.9 26.7 
38 39 M 615 8 EC,2FFP 88 21 8.3 10.9 19.9 
39 27 M 660 279 110 3.1 33.5 30.0 
40 65 F 720 6 EC,1 FFP 272 67 12.2 7.1 11.1 
41 53 M 1440* 4EC 350 90 18.1 13.6 18.6 
42 18 M 1680* 4EC 287 49 16.3 15.0 25.7 
8 Age Anesthesia Cabal. TCII FA HCY MET 
Nr (yrs) Sex (minutes) Transf. (pM) (pM) (nM) (!J.M) (!J.M) 
43 32 F 115 189 83 6.0 15.0 20.8 
44 54 M 125 475 163 24.2 11.6 21.6 
45 30 M 165 389 225 5.4 18.9 24.4 
46 40 M 195 167 23 23.8 13.2 14.7 
47 81 M 240 196 31 6.3 15.1 11.4 
48 24 F 245 213 41 17.8 8.1 13.4 
49 40 F 310 272 61 7.0 7.5 10.5 
50 35 M 370 171 16 5.3 9.6 19.0 
51 70 M 520 4EC 86 16 4.7 19.6 18.4 
52 18 M 540 2EC 138 14 15.7 11.7 14.0 
53 51 M 560 1 EC 184 23 14.2 16.4 21.4 
54 18 M 600 4EC 317 51 7.0 12.3 9.6 
A: Patients anesthetized with nitrous oxide, B: Patients anesthetized with total intravenous anesthesia Normal 
ranges far plasma total cobalamin: 120-800 pM., holotranscobalamin 11:20-220 pM., homocysteine: 5-15 uM., 
folate: 7 - 25 nM., methionine: 1 0 - 55 uM. *: total exposure time over a 3 day period. (EC: erythrocyte 
concentrate, FFP: fresh frozen plasma) 
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Methionine in plasma was determined in deproteinized plasma, by a method 
involving derivation of the amino acids with orthophtaldialdehyde, followed by 
reversed-phase liquid chromatography and fluorescence detection (13). 
FJCo cobalamin and e2SJI PGA were obtained from Becton Dickinson, Orangeburg, 
New York, USA Total cobalamin and cobalamin analogues in plasma were 
determined with a radioassay using purified intrinsic factor and salivary R-binder (14). 
Folate was also determined with a radioassay using milk-binder. Holotranscobalamin 
II was determinded according to van Kapel et al.(15). 
Statistical evaluation. Only patients undergoing one period of anesthesia were included 
in the statistical analysis. Differences between pre- and postoperative plasma values 
were statistically evaluated with the Wilcoxon signed rank test for paired observations. 
Urinary excretion of folate and homocysteine of the nitrous oxide and TIV A groups 
were tested with the Mann-Whitney U test. Percentage changes of plasma homo-
cysteine, folate and methionine, urinary folate and urinary homocysteine excretion 
were correlated with anesthesia duration using the Spearman rank correlation 
coefficent. 
To evaluate the long term effects of anesthesia, values at the start of anesthesia 
were tested against the values at the end and also 1, 2 and 7 days afterwards using 
the Wilcoxon signed rank test for paired observations. All p values are given as 
two-tailed. 
7 .4. Results 
Preoperative plasma values. Initial values for total cobalamin, holotranscobalamin II, 
folate, homocysteine and methionine are summarized in table 7.1. Three patients had 
a low plasma cobalamin, together with low holo-transcobalamin II. Two of these 
patients also had a subnormal methionine level. Folate concentrations were frequently 
below the normal range. Homocysteine above the normal range was observed in 10 
patients. The plasma folate concentrations correlated inversely with the homocysteine 
level (n=52, r,=-0.30, p<0,025). 
Effed of anesthesia on postoperative plasma parameters. In both groups of patients, 
total cobalamin and holotranscobalamin II had not significantly changed at the end of 
anesthesia. Increase in plasma concentration of cobalamin analogues was not 
observed. 
In patients anesthetized with TIV A, plasma folate decreased moderately (n = 12, 
p < 0,05) without significant changes in plasma homocysteine or methionine. 
During nitrous oxide exposure, postoperative levels of plasma homocysteine and 
folate significantly increased (figure 7.2 top and middle) (n=40, p<0.001). 
In only 5 out of 42 patients anesthetized with nitrous oxide the postoperative folate 
levels exceeded the normal range. In 35 of the 42 patients operated on under nitrous 
oxide the elevated homocysteine level surpassed the upper limit of the normal range. 
The percentage change in plasma homocysteine and folate correlated significantly 
Figure 7.2 (next page): Pre- and postoperative levels of plasma homocysteine, folate and methionine. A: 
Patients anesthetized with nitrous oxide (n=40), B: Patients anesthetized with total intravenous anesthesia 
(n=12). Normal range for plasma homocysteine: 5-15 J.LM., normal range for plasma folate: 7-25 nM., 
normal range for plasma methionine: 10-55 J.LM. 
89 
40 
A B 
... 
2 
- 30 
0 
E 
2 
Q) 
c 
] 20 
~ "' >-u 0 E 0 .c 
"' 
10 
E
==--"' 
"' a: 
0 
0 12 0 6 12 
30 
B 
... ~ 2 :;::: 20 0 E c 
2 
----"' ~ :E 
"' E
"' ..!!! 
a. ~-
0 6 12 0 12 
40 
A B 
... 
2 
- 30 
0 
E ~ 2 Q) .S 20 c 0 
:c ~ Ql E "' E 10 "' 
"' a: ~ 
...... 
0 
0 6 12 0 6 12 
Duration of anesthesia (hours) 
90 
300 -60 
• 
Ul • !... 
• ::::! 
-
0 
Ul 
..c !... r-
::::! .::!' 
0 N 
..c 
' 
.::!' 0 
N 200 r- E 40 
' 
;:1. 
0 • 
.._, 
E 
• 
Q) 
c c 
.._, 
Q) 
-~ Q) ..... ..... Ul • ro >- • 0 • u • '+- 100 • • ~ 20 • • >- .. • 0 !... 0 ..c o •••• ro 
• 0. 0 c >- • 0 •• o • !... o• • 0 !... 0 0 0 ro ~ co. • c oo 0 0 0 !... 0 0 ~ 
I 
0 6 12 0 6 12 
Duration of anesthesia (in hours) 
Figure 7 3: Urinary excretion of folate and homocysteine during the first 24 hours after start of 
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intravenous anesthesia (n=lO).) Normal urinary folate excretion: < 75 nmol/24 hrs. Normal urinary 
homocysteine excretion: 3.5-9.5 }Lmol/24 hrs. 
with nitrous oxide exposure time (n=40, r,=0.73, p<0.0001 and n=40, r,=0.36, 
p<0.025 respectively). Moreover, preoperative folate values inversely correlated with 
the absolute increase in plasma homocysteine concentrations (n=40, r,=-0.34, 
p<0.025). 
Interestingly, patient 41 and 42, who had been exposed to nitrous oxide for more 
than 24 hours within three days, showed a remarkable strong increase in plasma 
homocysteine (from 13.6 to 134.5 JLM and from 15.0 to 67.4 JLM respectively). Plasma 
folate only increased twofold (from 18.1 to 39.6 nM and from 16.3 to 27.7 nM). After 
the last nitrous oxide anesthesia, bone marrow smears from both patients revealed 
macrocytic changes. As reported by others (3), we found that during nitorus oxide 
exposure plasma methionine decreased (n=40, p<0.025) (figure 7.2, bottom). The 
percentage change in plasma methionine inversely correlated with the duration of 
nitrous oxide anesthesia (n=40, r,=- 0.29, p<0.025). 
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Figure 7.4: Time course of changes in studied plasma and urinary parameters in a patient (nr 25) 
anesthetized with nitrous oxide (left) and a patient (nr 49) anesthetized with total intravenous anesthesia 
(right). 
Effect of anesthesia on urinary excretion of folate and homocysteine. During the first 24 
hours after the start of anesthesia, the urinary folate (figure 7.3A) and homocysteine 
excretions (figure 7.3B) of patients anesthetized with nitrous oxide were significantly 
higher than those of patients anesthetized with TIV A (p < 0.002 and p < 0.01 
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Table 7.2: 
Plasma folate and homocysteine levels 1, 2 and 7 days after anesthesia 
with nitrous oxide or total intravenous anesthesia. 
PLASMA FOLATE (nM) PLASMA HOMOCYSTEINE (!JM) 
Group: N20 TIVA Np TIVA (n = 8) (n = 6) (n = 8) (n = 6) 
Start of 
anesthesia: 7.9 ± 1.3 10.8 ± 3.0 10.2 ± 0.6 13.1 ± 1.8 
End of 
anesthesia: 11.7 ± 1.9** 9.0 ± 2.3 18.0 ± 1.9** 11.1 ± 0.8 
1 day after 
anesthesia: 10.5 ± 1.2** 9.2 ± 2.6 18.4 ± 2.1** 8.9 ± 1.1* 
2 days after 
anesthesia: 8.0 ± 1.1 10.3 ± 3.0 15.6 ± 1.4** 12.0 ± 1.9 
1 week after 
anesthesia: 6.4 ± 1.3 N.D. 15.1 ± 1.6** N.D. 
(*: p < 0.05, **: p < 0.01) 
respectively). The increased homocysteine and folate excretion in the patients 
correlated with the duration of nitrous oxide anesthesia (n = 19, r, = 0.62, p < 0.005 and 
n=19, r,=0.60, p<O.Ol respectively). Postoperative plasma homocysteine, correlated 
with urinary homocysteine (n=19, r,=0.43, p<O.OS) whereas no correlation was found 
between postoperative plasma folate and urinary folate excretion. 
Tune course of induced changes. From six patients anesthetized with nitrous oxide for 
various time periods and 4 patients anesthetized with TIV A, blood samples were 
collected at regular intervals for 24 hours in order to study changes in plasma folate, 
homocysteine and methionine as a function of time. Figure 7.4 shows the typical 
results of patients anesthetized with nitrous oxide (left) and TIV A (right) respectively. 
In patients anesthetized with TIV A only minor fluctuations in the studied parameters 
occured and no significant pattern evolved. 
In patients operated on under nitrous oxide anesthesia, plasma methionine usually 
declined after a lag phase of 3-6 hours. Plasma folate and homocysteine progressively 
increased during nitrous oxide anesthesia. In most patients, maximal plasma folate 
and homocysteine were reached at the end or a few hours after termination of 
anesthesia. Then, plasma folate and homocysteine gradually declined. Increase and 
decrease of total homocysteine did not change the ratio between free and 
protein-bound homocysteine (figure 7.4). 
From the same group of 6 patients operated on under nitrous oxide anesthesia and 
4 patients operated on under TIV A, fractionated urine was collected during 24 hours 
for determination of folate and homocysteine excretion. Elevated homocysteine and 
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folate excretion occured several hours after the start of nitrous oxide anesthesia 
(figure 7.4, left), causing up to 20-fold increase of urinary concentrations of both 
compounds. In patients anesthetized with TIV A only diurnal variations in urinary 
folate and homocysteine excretion occured (figure 7.4, right). 
Long term effects. From 8 patients operated on under nitrous oxide anesthesia and 
from 6 patients operated on under TIV A, plasma homocysteine and plasma folate 
were determined 1 day, 2 days and 1 week after anesthesia (table 7.2). No specific 
patterns developed in the group of patients anesthetized with TIV A In patients 
anesthetized with nitrous oxide anesthesia, elevated plasma folate levels usually 
returned to preoperative values within 2 days. However, in all patients anesthetized 
with nitrous oxide plasma homocysteine was still increased 2 days and one week after 
anesthesia (n=8, p< 0.01). 
7.5. Discussion 
Nitrous oxide is the only compound known to inactivate the methylcobalamin 
coenzyme of methionine synthase which is an important enzyme of the folate 
metabolism. Possible side effects of this interaction are clinically relevant, in view of 
the widespread application of nitrous oxide in anesthesia. 
Earlier studies have shown that in fit surgical patients, disturbance of the folate-
dependent thymidylate synthesis occurs after 5-6 hours of nitrous oxide anesthesia 
(16). Megaloblastic bone marrow changes occur in fit patients after exposure to 
nitrous oxide for 12-24 hours. The chance that anesthesia including nitrous oxide 
becomes hematotoxic is generally considered to be small because duration of nitrous 
oxide exposure is usually too short to interfere seriously with the 
cobalamin-dependent folate metabolism. However, the rapid rise of plasma 
homocysteine and folate during 1litrous oxide anesthesia found in this study indicates 
that perturbation of folate and homocysteine metabolism develops with little delay. 
The megaloblastic bone marrow changes seen in critically ill patients after less than 2 
hours exposure nitrous oxide (5) and the highly increased bone marrow toxicity of 
methotrexate when administered after nitrous oxide anesthesia may well be attributed 
to this phenomenom (17,18). 
The observed differences in the individual response to nitrous oxide induced 
cobalamin inactivation concurs with the observation of Nunn et al. who showed that 
the rate of methionine synthase inhibition during nitrous oxide anesthesia is variable 
(19). In addition, this phenomenom may be related to the differences in the existing 
cobalamin and folate status because in our study low preoperative folate correlated 
positively with the increase of plasma homocysteine during nitrous oxide anesthesia. 
Apparently, low preoperative plasma folate reflects a relative lack of intracellular 
folates which aggrevates the effects of nitrous oxide on the cobalamin-dependent 
methylation of homocysteine. 
The plasma homocysteine levels after nitrous oxide exposure frequently increased 
above normal. In several patients the plasma homocysteine levels were comparable 
with those in cobalamin deficiency (9). These findings further support the suggestion 
that plasma homocysteine may be a useful parameter to measure disturbances of the 
cobalamin-dependent folate metabolism (9). Concentration of homocysteine in urine 
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may also be a good indicator as the enhanced renal excretion of this amino acid 
strongly correlates with duration of nitrous oxide anesthesia. The demonstrated 
increase in urinary folate agrees with similar observations in rats (20) but is difficult 
to explain as folate plasma values rarely became abnormal. Possibly, the reuptake of 
urinary folates by renal tubular cells is also affected by the inhibition of methionine 
synthase causing elevated excretion. 
In most tissues, the cobalamin-dependent methylation of homocysteine to 
methionine is a quantitatively important pathway of homocysteine disposal (21). Our 
finding that plasma homocysteine is still elevated one week after nitrous oxide 
anesthesia implies that methionine synthase activity recovers very slowly. Slow 
recovery of enzyme activity may explain why the increase of plasma homocysteine was 
most pronounced in our 2 patients receiving multiple nitrous oxide exposures. 
Notably, subjects who have repeatedly been exposed to nitrous oxide within a short 
period, become particularly vulnerable to developing megaloblastosis (22,23). 
In summary, this study demonstrates that the effect of cobalamin inactivation by 
nitrous oxide can be monitored by the rapid increase in plasma homocysteine. In 
addition, it shows that nitrous oxide anesthesia perturbs cobalamin-dependent folate 
and homocysteine metabolism at a faster rate than has been hitherto re cognized and 
that recovery of methionine synthase activity probably requires several days, even 
after short exposure. 
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Chapter 8 
General discussion 
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Cobalamin, or vitamin B12, is a coenzyme of methionine synthase. This enzyme 
concomitantly converts homocysteine and 5-methyltetrahydrofolate to methionine and 
tetrahydrofolate. The latter favors the polyglutamation of intracellular folates to less 
exchangeable forms and can be converted to other folate coenzymes. Several steps in 
the de novo synthesis of thymidylate and purines, necessary for DNA-replication and 
RNA-synthesis respectively, require folate coenzymes. In man, the proliferation of the 
hematopoietic compartment is very dependent on the intact function of the 
cobalamin-dependent folate metabolism as is clear from the megaloblastic bone 
marrow depression which may develop during cobalamin or folate deficiency. 
The anesthetic gas nitrous oxide is capable to oxidize the monovalent cobalt atom 
of the cobalamin coenzyme of methionine synthase. This inactivation of cobalamin 
causes the complete inhibition of methionine synthase activity. It has been shown that 
prolonged exposure to nitrous oxide can therefore produce megaloblastic changes in 
the bone marrow, similar to cobalamin deficiency. 
The widespread clinical use of nitrous oxide has evoked general interest in possibly 
toxic side effect of this anesthetic gas. Since the discovery of in vivo cobalamin 
inactivation by nitrous oxide in 1978, extensive investigations on the hematological 
and metabolic consequences of this phenomenom have been performed. However, 
most clinical studies have focused on nitrous oxide exposure periods of 12-24 hours 
(1,2) and metabolic studies usually have been performed in test animals. 
In the present thesis the possible hematological and metabolic effects of shorter 
periods of nitrous oxide exposure were investigated in patients anesthetized with 
nitrous oxide (chapter 6, 7). The determination of bone marrow progenitors and 
plasma homocysteine in patients anesthetized with nitrous oxide allowed a more 
accurate evaluation of the effects of cobalamin inactivation. It can be concluded that 
nitrous oxide exposure up to 12 hrs changes the proliferation kinetics of the 
hematopoietic progenitors but does not disturb normal bone marrow function. 
However, the sustained elevation of plasma homocysteine one week after anesthesia 
indicates that nitrous oxide may result in long term inhibition of the 
cobalamin-dependent remethylation of homocysteine to methionine. 
The importance of the various folate coenzymes for the DNA synthesis of 
proliferating cells makes them an attractive target in cancer chemotherapy. This is 
illustrated by the current application of several structural analogues of reduced folates 
(e.g. methotrexate) in the treatment of cancer. Studies on the possible application of 
cobalamin inactivation in the treatment of malignant diseases has always been 
hampered by the absence of biologically active cobalamin antagonists. The discovery 
that nitrous oxide effectively disturbs the coenzyme function of cobalamin in 
methionine synthase provides a tool to study cobalamin inactivation as a potential 
target in cancer chemotherapy. 
Kroes et al. (3) have shown that exposure to nitrous oxide may reduce the 
proliferation of leukemic cells in a rat model for myeloid leukemia. Moreover they 
demonstrated that the antileukemic effect of nitrous oxide may be further enhanced 
by combinations with drugs (4-7) which interfere with other steps of the one carbon 
metabolism. Especially the antiproliferative effect of nitrous oxide in combination 
with 5-fluorouracil, an inhibitor of the folate-dependent enzyme thymidylate synthase 
or with methotrexate, which inhibits the enzyme dihydrofolate reductase, was striking. 
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This potentiation of methotrexate by nitrous oxide in a rat leukemia model (5) 
initiated further research on this particular drug interaction. Studies in normal rats 
(chapter 3) reveal that the cytotoxicity of the nitrous oxide-methotrexate combination 
is restricted to dividing cells. Biochemical investigations in fresh human leukemic cells 
(chapter 4,5) show that the antiproliferative effect of nitrous oxide-methotrexate 
interaction is probably based on the disturbance of the cellular folate metabolism 
(chapter 5) impairing the folate- dependent thymidylate synthesis (chapter 4 ). The 
observed accumulation of hematopoietic progenitors in nitrous oxide exposed rats 
(chapter 3) concurs with a similar accumulation of both myeloid and erythroid 
progenitors in patients exposed to nitrous oxide (chapter 6). This finding suggests 
synchronisation of progenitor cells and may also contribute to observed myelotoxicity 
of methotrexate in nitrous oxide- exposed patients (8). Altogether the results of these 
studies contribute to a better understanding of the unexpected toxic side effects which 
may be seen in patients treated with methotrexate shortly after or during anesthesia 
including nitrous oxide (8). In addition, the presented data support earlier suggestions 
(5,9) on the possible application of combined nitrous oxide-methotrexate exposure in 
the chemotherapeutic treatment of malignancies. 
The application of cobalamin inactivation by nitrous oxide in the treatment of 
hematological malignancies in humans has only been studied casually (10,11,12). 
Exposure of leukemic rats of the Brown Norway Myeloid Leukemia model to nitrous 
oxide shows that leukemic cells are more sensitive to nitrous oxide than normal 
hematopoietic cells (chapter 2). This finding suggests that in humans, leukemic 
proliferation may also be more vulnerable towards the effects of nitrous 
oxide-induced cobalamin inactivation. 
The present thesis provides in vitro evidence that the cobalamin- dependent folate 
metabolism of most types of human leukemia is sensitive to nitrous oxide; besides 
disturbance of the folate dependent thymidylate synthesis (chapter 4 ), a significant 
redistribution of the various intracellular folate coenzymes has been demonstrated 
(chapter 5). In addition it is shown that nitrous oxide exposure up to 12 hours hardly 
interferes with normal hematopoiesis (chapter 6). 
Altogether, the acquired knowledge on this subject has reached the point of which 
the experimental application of nitrous oxide in the chemotherapy of human leukemia 
seems justified. The existing clinical data on nitrous oxide exposure of leukemia 
patients (10,11,12) suggest that effective treatment requires long (intermittent) 
exposure periods. Today, a massive amount of information exists on the toxic effects 
of nitrous oxide on normal bone marrow function. However, the effect of 
cobalamin-inactivation on residual normal hematopoiesis in acute leukemia has only 
been studied in rats (chapter 2). The experimental use in cancer chemotherapy 
therefore requires a careful approach. This thesis shows that determination of plasma 
homocysteine may provide a reliable and practical tool to monitor the process of 
cobalamin inactivation during exposure to nitrous oxide. Moreover, earlier studies 
(13) have shown that effects of nitrous oxide-induced cobalamin inactivation in man 
can easily be curtailed by the administration of 5- formyltetrahydrofolate. The 
availability of this effective antidote in case of nitrous oxide-induced bone marrow 
depression further favors the treatment of a selected group of leukemia patients with 
nitrous oxide exposure. 
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The use of an anesthetic gas for chemotherapeutic purposes may be considered 
unpractical. Still, the extensive knowledge on the administration of nitrous oxide 
among anesthesiologists should make its application feasible. In this way, the common 
interest among hematologists and anesthesiologist for the toxic side effects of nitrous 
oxide-induced cobalamin inactivation may perhaps evolve in a interdisciplinary 
method to reduce the proliferation of malignant blood cells. 
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SUMMARY 
This thesis deals with the biochemical and clinical sequelae of nitrous oxide-induced 
cobalamin inactivation. Cobalamin or vitamin B,2 is, as methylcobalamin a necessary 
coenzyme in methionine synthase. This particular enzyme converts internalized 
5-methyltetrahydrofolate to tetrahydrofolate, which can further be metabolized to 
other, less exchangeable folate forms. In this reaction homocysteine is concomitantly 
methylated to methionine. Several steps in the biosynthesis of nucleotides which are 
necessary for DNA replication, require folate coenzymes. The immediate importance 
of cobalamin-dependent folate metabolism for proliferating cells is evidenced by its 
principal role in the maintenance of human hematopoiesis. As far as known, the 
anesthetic gas nitrous oxide is the only agent capable of inactivating the 
methylcobalamin coenzyme. Nitrous oxide thereby reduces methionine synthase 
activity and disturbs intracellular folate metabolism. In humans, prolonged exposure 
to nitrous oxide leads to impaired hematopoiesis as a result of decreased 
folate-dependent thymidylate synthesis, and hence DNA replication. 
In chapter 1 the biochemistry of cobalamin-dependent folate metabolism and the 
biochemical and clinical effects of nitrous oxide exposure are reviewed. 
In chapter 2, studies on the differential effect of nitrous oxide on normal and 
malignant hematopoiesis are presented. It was shown that significant reduction of 
leukemic proliferation can be achieved in the Brown Norway Myeloid Leukemia rat 
model for myeloid leukemia by exposure to 50% nitrous oxide/50% oxygen. This 
treatment did not further enhance the suppression of normal hematopoiesis which 
already was present because of the leukemic bone marrow infiltration. In normal rats 
a similar exposure to nitrous oxide also did not suppress normal hematopoiesis as 
wittnessed by peripheral blood parameters and hematopoietic progenitor cells present 
in the bone marrow. The BNML is considered to be a good model for the 
chemotherapeutic response of human myeloid leukemia. We therefore concluded that 
the presented data may also implicate a greater sensitivity of human leukemia for 
nitrous oxide-induced cobalamin inactivation compared with normal hematopoiesis. 
Chapter 3 contains the results of an extensive toxicological study on the interaction 
between nitrous oxide and the folate antagonist methotrexate. It was shown that 
nitrous oxide exposure of rats for 48 hours decreased the LD50 of methotrexate from 
60 mgfkg to 10 mg/kg. Major toxicity occurred in the gastrointestinal tract, causing 
severe diarrhoea, and the bone marrow, causing leucocytopenia and 
thrombocytopenia. No important damage to liver or kidney occurred. Lethal toxicity 
could be prevented by the administration of 5-formyl THF. It was concluded from this 
study that as nitrous oxide strongly potentiates the cytotoxicity of methotrexate, the 
unintentional use of this anesthetic gas shortly before or during treatment with 
methotrexate should be avoided. However, the antiproliferative effect of the nitrous 
oxide-methotrexate combination merits further investigation of its possible application 
in the treatment of malignancies. 
In chapter 4 the effect of nitrous oxide on the folate metabolism of human 
leukemia cells was studied in vitro, employing the deoxyuridine suppression test. 
Leukemic cells from bone marrow and peripheral blood of 18 patients and from the 
myelomonocytic cell line U937 were exposed to nitrous oxide for 20 hours before they 
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were subjected to the deoxyuridine suppression test. In all leukemic samples, nitrous 
oxide induced at least 200% increase of the deoxyuridine suppression test value, 
implicating a disturbance of folate-dependent thymidylate synthesis. Incubation of 
leukemic cells with drugs, which interfere with the one-carbon metabolism 
(methotrexate, 5-fluorouracil, cycloleucine) also caused decrease of folate-dependent 
thymidylate synthesis which was further enhanced by concomitant exposure to nitrous 
oxide. From these data it appeared that many types of human leukemia are sensitive 
to cobalamin inactivation by nitrous oxide. Moreover it was concluded that the effect 
of drugs interfering with folate metabolism on the folate- dependent thymidylate 
synthesis, may be enhanced by nitrous oxide. 
Further biochemical investigations on the effects of nitrous oxide and methotrexate 
on the folate metabolism of leukemic cells are presented in chapter 5. Folate pools of 
blast cells from 10 cases of acute myeloid leukemia and 5 cases of lymphoid leukemia 
were radiolabeled by incubation with rHJ 5-formyltetrahydrofolate. Folate pools were 
subsequently analysed by means of High Performance Liquid Chromatography. It was 
found that concentrations of 10-formyltetrahydrofolate and dihydrofolate in cells from 
acute myeloid leukemia and acute lymphoid leukemia are significantly different. 
Incubation of the radiolabeled leukemic cells with nitrous oxide or methotrexate 
caused accumulation of respectively 5-methyltetrahydrofolate or dihydrofolate, at the 
expense of other folate forms. The presence of substantially more dihydrofolate in 
cells from acute lymphoid leukemia together with a specific decrease of 10-
formyltetrahydrofolate during methotrexate treatment probably contributes to the 
efficacy of methotrexate in the treatment of acute lymphoid leukemia. 
Chapter 6 presents a clinical study in which the effects of nitrous oxide anesthesia 
for 7-12 hours on normal hematopoiesis were investigated. Bone marrow samples 
from 14 patients operated on under nitrous oxide were obtained at start and end of 
surgery. Macrocytic changes of the bone marrow cells only occurred in 2 patients 
exposed to nitrous oxide for more than 24 hours in a three day period. Disturbed 
deoxyuridine suppression test values were noticed in all patients operated on under 
nitrous oxide anesthesia but not in the control group of 4 patients operated on under 
total intravenous anesthesia. Myeloid and erythroid progenitors present in the bone 
marrow and cultured in vitro, increased during nitrous oxide exposure of patients with 
normal plasma cobalamin and folate levels. However, in patients with a low plasma 
cobalamin and/ or folate level, both type of hematopoietic progenitors decreased in 
bone marrow during nitrous oxide exposure. Still, the number of progenitor cells 
present in bone marrow after nitrous oxide exposure never decreased below the lower 
limit of normal values. It was therfore concluded that although nitrous oxide induced 
changes in the proliferation kinetics of the hematopoietic progenitor cells, the toxic 
effect of this anesthetic gas on hematopoiesis is rather limited within the studied 
exposure periods. 
Chapter 7 comprises an extensive study on the effects of nitrous oxide anesthesia 
on homocysteine and folate levels in plasma and urine of surgical patients. In patients 
subjected to anesthesia with nitrous oxide or operated on under total intravenous 
anesthesia, plasma levels of homocysteine, methionine and folate were determined at 
start and end of anesthesia. It was found that already short term nitrous oxide 
exposure elevated plasma homocysteine and folate and decreased plasma methionine. 
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Increased urinary excretion of both folate and homocysteine was also observed. 
Moreover it was shown that plasma levels of homocysteine and folate continued to 
rise for several hours after withdrawal of nitrous oxide anesthesia. As the increase in 
plasma homocysteine correlated highly with the length of nitrous oxide exposure, it 
was concluded that the rise of plasma homocysteine is a reliable indicator for nitrous 
oxide-induced cobalamin inactivation. Moreover, the presented data suggested that 
effects of nitrous oxide on homocysteine and folate metabolism develop more rapidly 
than presently supposed. 
Finally in chapter 8 the results of these investigations are discussed in view of the 
current knowledge on the role of the cobalamin-dependent folate metabolism in 
normal and malignant hematopoiesis. 
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SAMENVATIING 
Cobalamine, of vitamine B12 speelt een belangrijke rol in de intracellulaire 
foliumzuurstofwisseling door zijn functie als coenzym van methionine synthase. Dit 
enzym is van essentieel belang voor het behoud van intracellulaire gereduceerde 
foliumzuurvormen. Nieuw opgenomen 5-methyltetrahydrofolaat wordt door 
methionine synthase gedemethyleerd tot tetrahydrofolaat en vervolgens omgezet in 
andere folaatvormen welke minder snel de eel kunnen verlaten. Verschillende folaten 
zijn als coenzym betrokken by de biosynthese van nucleotides, welke noodzakelijk zijn 
voor DNA synthese. De instandhouding van de humane hematopoese is dan ook 
afhankelijk van een normale- activiteit van het cobalamine coenzym in de 
foliumzuurstofwisseling. Voor zover bekend is het anestheticum lachgas de enige 
verbinding die in staat is het cobalamine coenzyme van methionine synthase te 
inactiveren. Lachgas remt daardoor de aktiviteit van het enzym methionine synthase 
en kan zodoende de intracellulaire foliumzuurstofwisseling verstoren. Bij de mens 
leidt langdurige lachgasblootstelling tot een verminderde hematopoese doordat de 
foliumzuurafhankelijke thymidylaatsynthese verstoord raakt en daarmee de DNA 
replicatie geremd. 
In dit proefschrift worden studies beschreven welke betrekking hebben op de 
hematologische, biochemische en klinische facetten van lachgas geinduceerde 
cobalamine inactivatie. Hoofdstuk 1 omvat een overzicht van de biochemie van de 
cobalamine afhankelijke foliumzuurstofwisseling. Tevens worden hierin de huidige 
inzichten in de biochemische en klinische gevolgen van lachgasblootstelling samen-
gevat. 
In hoofdstuk 2 worden studies met betrekking tot het differentiele effect van 
lachgas op de normale en maligne ( = leukemische) hematopoese gepresenteerd. 
Indien leukemische ratten van het Brown Norway Myeloid Leukemia rattemodel 
blootgesteld werden aan een gasmengsel van 50% lachgas/50% zuurstof, trad er een 
duidelijk vertraging van het leukemische proces op. Tevens werd waargenomen dat 
lachgas blootstelling van de leukemische BN ratten geen extra schade toebracht aan 
de normale hematopoese welke onder invloed van de leukemische beenmerginfiltratie 
reeds sterk verminderd was. In gezonde BN ratten had lachgas evenmin nadelige 
effecten of de normale hematopoese, hetgeen onderzocht werd aan de hand van 
perifere bloedparameters en het aantal aanwezige hematopoetische voorlopercellen in 
het beenmerg. Aangezien het BNML ratteleukemie model beschouwd wordt als een 
goed model voor de chemotherapeutische respons van myeloide leukemie, lijken de 
beschreven bevindingen te wijzen op een grotere gevoeligheid van humane leukemie 
voor lachgas geinduceerde cobalamine inactivatie dan voorlopercellen van de normale 
hematopoese. 
Hoofdstuk 3 be:vat de resultaten van een studie naar de toxicologische interactie 
tussen lachgas en de foliumzuurantagonist methotrexaat. In ratten welke voor 48 uur 
aan lachgas waren blootgesteld verminderde de LD50 waarde voor methotrexaat van 
60 mgjkg naar 10 mgjkg. Toxiciteit trad met name op in de darmen, met ernstige 
diarrhee als gevolg, en in het beenmerg hetgeen tot leukopenie en thrombopenie 
leidde. Toxiciteit voor lever en nieren was niet aantoonbaar. Lethale effecten van de 
lachgas-methotrexaat combinatie konden voorkomen worden door de toediening van 
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5-formyltetrahydrofolaat. Deze studie toonde duidelijk aan dat lachgas in staat is de 
cytotoxiciteit van methotrexaat te potentieren. Gekonkludeerd werd dat het 
onbedoelde gebruik van lachgas in combinatie met methotrexaat voorkomen moet 
worden. De toepassing van de lachgas-methotrexaat combinatie in de chemothera-
peutische behandeling van maligniteiten verdient echter verdere studie. 
In hoofdstuk 4 wordt het in vitro effect van lachgas op de foliumzuurstofwisseling 
van humane leukemiecellen bestudeerd met behulp van de deoxyuridine 
suppressietest. Leukemiecellen uit het beenmerg en/ of bloed van 18 patienten en van 
de myelomonocytaire cellijn U937 werden gedurende 20 uur blootgesteld aan lachgas 
waarna de deoxyuridine suppressie van de thymidine inbouw werd gemeten. In aile 
gevailen veroorzaakte de lachgasblootstelling een verhoging van de deoxyuridine 
suppressietestwaarde van ongeveer 200%, hetgeen een sterke verstoring van de 
foliumzuurafhankelijke thymidylaatsynthese impliceert. Indien leukemische cellen 
werden geincubeerd met andere verbindingen die interferen met de folium-
zuurstofwisseling (methotrexaat, 5- fluorouracil, cycloleucine) trad er eveneens een 
verstoring van de foliumzuurafhankelijke thymidylaat synthese op welke versterkt kon 
worden door de gelijktijdige blootstelling aan lachgas. De gepresenteerde gegevens 
duiden erop dat bijna aile vormen van humane leukemie gevoelig zijn voor 
lachgas-geinduceerde cobalamine inactivatie. Tevens kan geconcludeerd worden dat 
de effecten van enkele verbindingen die eveneens interfereren met de fo-
liumzuurstofwisseling versterkt kunnen worden met lachgas. 
Hoofdstuk 5 bevat de resultaten van verdergaande biochemische studies naar de 
effecten van lachgas en/ of methotrexaat op de foliumzuurstofwisseling van humane 
leukemiecellen. De intracellulaire foliumzuurvormen van leukemiecellen afkomstig 
van 10 acute myeloide leukemieen en 5 lymfatische leukemieen werden radioactief 
gemerkt door incubatie met fH]5-formyltetrahydrofolaat. De verschillende 
foliumzuurvormen werden vervolgens gekwantificeerd met behulp van een High 
Performance Liquid Chromatography-scheiding. Cellen van acute myeloide en 
lymfatische leukemie verschilden duidelijk in de verdeling van foliumzuurcoenzymen. 
Blootstelling van leukemische cellen aan lachgas of methotrexaat veroorzaakte de 
intracellulaire ophoping van respectievelijk 5-methyltetrahydrofolaat en dihydrofolaat 
ten koste van de andere foliumzuurvormen. In cellen van acute lymfatische 
leukemieen werden aanzienlijke concentraties dihydrofolaat aangetoond. Tevens werd 
in cellen van deze vorm van leukemie tijdens blootstelling aan methotrexaat een 
specifieke daling van 10-formyltetrahydrofolaat waargenomen. Deze waamemingen 
kunnen mogelijkerwijs de relatief grote effectiviteit van methotrexaat in de behan-
deling van lymfatische leukemie mede verklaren. 
Hoofdstuk 6 omvat de resultaten van een klinische studie waarin bet effect van 
lachgasblootstelling op de normale hematopoese onderzocht werd. Van 14 patienten 
welke geopereerd werden onder anesthesie met lachgas (varierend van 7-12 uur) werd 
aan bet begin en aan het einde van de ingreep beenmerg afgenomen. Macrocytaire 
veranderingen van het beenmerg werd aileen waargenomen in 2 patienten welke 
meer dan 24 uur lachgasblootstellingen ondergingen in een tijdsbestek van 3 dagen. 
De deoxyuridine suppressietest was na afloop van de anesthesie aileen verstoord in 
beenmergcellen van patienten welke aan lachgas blootgesteld waren. In de 4 controle 
patienten welke geopereerd waren onder totale intraveneuze narcose trad geen 
108 
verandering in de deoxyuridine suppressietestwaarde op. In patienten met normale 
plasma cobalamine en foliumzuur waarden veroorzaakte de lachgasblootstelling een 
stijging van bet aantal erythroide en myeloide voorlopercellen in bet beenmerg. In 
patienten met lage plasma cobalamine en foliumzuur waarden leidde 
lachgasblootstelling tot een daling van deze hematopoetische voorlopercellen in bet 
beenmerg. Het aantal voorlopercellen in bet beenmerg bleef bij praktisch alle 
patienten echter binnen bet normaalwaarden gebied De bevindingen van deze studie 
impliceren een verandering in de proliferatiekinetiek van de hematopoetische 
voorlopercellen tijdens lachgasblootstelling. Binnen de bestudeerde blootstel-
lingsperiode (7-12 uur) blijkt bet hematotoxische effect van lachgas voor niet ernstig 
zieke patienten gering. 
Hoofdstuk 7 beschrijft een onderzoek naar de effecten na lachgas anesthesie op 
homocysteine en foliumzuurconcentraties in bloed en urine van operatie patienten. 
Daartoe werd van een aantal patienten die geopereerd werden onder anesthesie met 
lachgas en van een aantal patienten die geopereerd werden onder totale intraveneuze 
anesthesie aan bet begin en eind van de ingreep bloed afgenomen van de bepaling 
van homocysteine, foliumzuur en methionine in plasma. AI na kortdurende lachgas-
blootstelling (75 minuten) bleken homocysteine en foliumzuur gestegen te zijn terwijl 
plasma methionine daalde. De excretie van homocysteine en foliumzuur via de urine 
was in de patienten die anesthesie met lachgas ondergingen eveneens gestegen. 
Afname van plasma homocysteine en foliumzuur na afloop van de lachgas anesthesie 
verliep meestal zeer langzaam. De toename in plasma homocysteine correleerde zeer 
sterk met de blootstellingsduur aan lachgas. Plasma homocysteine werd daarom 
beschouwd als een indicator voor cobalamine inactivatie. Tevens blijkt uit de 
gepresenteerde gegevens dat de effecten van lachgas op de homocysteine en 
foliumzuurstofwisseling zich sneller manifesteerden dan tot nu toe werd aangenomen. 
In hoofdstuk 8 worden de resultaten van dit proefschrift besproken in samenhang 
met de huidige kennis omtrent de rol van de cobalamine-afhankelijke 
foliumzuurstofwisseling in de normale en maligne hematopoese. 
CURRICULUM VITAE 
De schrijver van dit proefschrift werd op 30 juli 1959 geboren te Bavel. Hij doorliep 
de middelbare school in Breda en behaalde in 1977 het eindexamen Atheneum-B aan 
de Newman scholengemeenschap. In 1978 werd begonnen met de studie biologie aan 
de Rijks Universiteit Utrecht. Na het behalen van het kandidaatsexamen in 1982 werd 
de studie voortgezet aan de Landbouwhogeschool te Wageningen. Het ingenieurs-
examen werd aldaar in 1985 afgelegd. Vanaf april 1985 tot jan 1990 werd het hier 
beschreven onderzoek verricht op het Instituut Hematologie van de Erasmus Univer-
siteit Rotterdam onder leiding van Prof.dr. J. Abels en dr. J. Undemans. 

NAWOORD 
Het hier voor u liggende proefschrift had nooit tot stand gekomen zonder de hulp van 
een groat aantal personen. 
Mijn promotor Prof.dr. J. Abels wi1 ik bedanken voor de mogelijkheid die hij mij 
gegeven heeft bet bier beschreven onderzoek te verrichten en de kritische wijze 
waarop hij bet manuscript van dit proefschrift heeft beoordeeld. 
Dr. J. Lindemans ben ik zeer erkentelijk voor bet gestelde vertrouwen en de 
bijzonder prettige begeleiding en samenwerking gedurende de gehele onderzoeksfase. 
Prof.dr. P.M. Ueland, Prof.dr. J.H.P. Wilson en Prof.dr. H.G. van Eijk bedank ik 
voor de beoordeling van bet concept van bet proefschrift. 
De medewerkers van bet hematologische researchlaboratorium Martijn Schoester, 
Lidwien Spijkers, Nel vink, Jan van Kapel en Martin Schipperus wi1 ik bedanken voor 
de efficiente, maar bovenal ludieke, wijze waarop ze de afgelopen periode met mij 
hebben samengewerkt. 
Kirsten van Lorn, Kees de Leeuw, Jeanne Vlasveld en alle andere medewerkers 
van Hematologie-Dijkzigt ben ik dankbaar voor hun belangeloze collegialiteit en 
interesse. 
Dr. AC.M. Kroes wi1 ik bedanken voor de enthousiaste wijze waarop hij mij 5 jaar 
geleden introduceerde in bet vakgebied van de hematologie en de wijze waarop hij 
mij sindsdien steeds met raad terzijde heeft gestaan. 
Dr. J. Rupreht ben ik zeer erkentelijk voor de prettige en vruchtbare samenwerking 
welke van doorslaggevende betekenis waren voor bet hier beschreven klinische 
onderzoek. 
Tenslotte wil ik de medewerkers van bet A VC, bet CPB en bet ERC bedanken 
voor hun onmisbare hulp. 

